Evofem Biosciences (EVFM) 10-K 1 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Feb. 22, 2019	Jun. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Registrant Name	EVOFEM BIOSCIENCES, INC.
Entity Central Index Key	1,618,835
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 16,035,680
Common stock, shares outstanding		28,156,567

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,330	$ 1,211
Restricted cash	431	490
Prepaid and other current assets	717	653
Total current assets	2,478	2,354
Property and equipment, net	593	848
Other noncurrent assets	939	750
Total assets	4,010	3,952
Current liabilities:
Accounts payable	8,882	8,999
Note payable	4,010	0
Accrued expenses	11,513	12,086
Accrued compensation	2,924	2,392
Series D 2X liquidation preference	0	79,870
Total current liabilities	27,329	103,347
Deferred rent	37	114
Other noncurrent liabilities	0	166
Total liabilities	27,366	103,627
Commitments and contingencies (Note 6)
Stockholders’ deficit:
Common stock, $0.0001 par value; 300,000,000 and 4,051,137 shares authorized at December 31, 2018 and 2017, respectively; 25,867,248 and 2,082,053 shares issued and outstanding at December 31, 2018 and 2017, respectively	3	0
Additional paid-in capital	409,787	17,731
Accumulated deficit	(433,146)	(307,277)
Total stockholders’ deficit	(23,356)	(289,546)
Total liabilities, convertible preferred stock and stockholders’ deficit	4,010	3,952
Series A Convertible Preferred Stock
Preferred stock, $0.0001 par value; 5,000,000 and 57,501,624 shares authorized at December 31, 2018 and 2017, respectively:
Convertible preferred stock, value	0	23,848
Series B Convertible Preferred Stock
Preferred stock, $0.0001 par value; 5,000,000 and 57,501,624 shares authorized at December 31, 2018 and 2017, respectively:
Convertible preferred stock, value	0	43,616
Series C-1 Convertible Preferred Stock
Preferred stock, $0.0001 par value; 5,000,000 and 57,501,624 shares authorized at December 31, 2018 and 2017, respectively:
Convertible preferred stock, value	0	34,382
Series C Convertible Preferred Stock
Preferred stock, $0.0001 par value; 5,000,000 and 57,501,624 shares authorized at December 31, 2018 and 2017, respectively:
Convertible preferred stock, value	0	19,469
Series D Convertible Preferred Stock
Preferred stock, $0.0001 par value; 5,000,000 and 57,501,624 shares authorized at December 31, 2018 and 2017, respectively:
Convertible preferred stock, value	$ 0	$ 68,556

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2018	Jan. 17, 2018	Dec. 31, 2017
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000	4,051,137
Common stock, shares issued	25,867,248		2,082,053
Common stock, shares outstanding	25,867,248		2,082,053
Preferred Stock
Convertible preferred stock, par value (in dollars per share)	$ 0.0001		$ 0.0001
Convertible preferred stock, shares authorized	5,000,000		57,501,624
Convertible preferred stock, shares issued			40,016,147
Convertible preferred stock, shares outstanding			40,016,147
Preferred Stock | Series A Convertible Preferred Stock
Convertible preferred stock, shares issued	0		12,618,279
Convertible preferred stock, shares outstanding	0		12,618,279
Preferred Stock | Series B Convertible Preferred Stock
Convertible preferred stock, shares issued	0		13,801,318
Convertible preferred stock, shares outstanding	0		13,801,318
Preferred Stock | Series C-1 Convertible Preferred Stock
Convertible preferred stock, shares issued	0		8,558,686
Convertible preferred stock, shares outstanding	0		8,558,686
Preferred Stock | Series C Convertible Preferred Stock
Convertible preferred stock, shares issued	0		5,037,784
Convertible preferred stock, shares outstanding	0		5,037,784
Preferred Stock | Series D Convertible Preferred Stock
Convertible preferred stock, shares issued	0		80
Convertible preferred stock, shares outstanding	0		80

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating expenses:
Research and development	$ 43,415	$ 23,539
General and administrative	34,227	12,148
Total operating expenses	77,642	35,687
Loss from operations	(77,642)	(35,687)
Other income (expense):
Interest income	127	128
Other expense, net	(145)	(46)
Loss on issuance of Series D redeemable convertible preferred stock	0	(8,522)
Loss on issuance of warrants	(47,920)	0
Change in fair value of Series D 2X liquidation preference	(130)	(61,175)
Total other expense, net	(48,068)	(69,615)
Loss before income tax	(125,710)	(105,302)
Income tax expense	(2)	(3)
Net loss	(125,712)	(105,305)
Accretion of Series D redeemable convertible preferred stock dividends	(66)	(4,017)
Net loss attributable to common stockholders	$ (125,778)	$ (109,322)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (5.74)	$ (55.78)
Weighted-average shares used to compute net loss attributable to common stockholders, basic and diluted (in shares)	21,900,574	1,959,904

CONSOLIDATED STATEMENTS OF CONV

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Series A Convertible Preferred StockPreferred Stock	Series B Convertible Preferred StockPreferred Stock	Series C-1 Convertible Preferred StockPreferred Stock	Series C Convertible Preferred StockPreferred Stock	Series D Redeemable Convertible Preferred StockPreferred Stock	Invesco Asset Management	Invesco Asset ManagementCommon Stock	Invesco Asset ManagementAdditional Paid-In Capital	Private Placement	Private PlacementCommon Stock	Private PlacementAdditional Paid-In Capital	Public Offering	Public OfferingCommon Stock	Public OfferingAdditional Paid-In Capital
Beginning balance at Dec. 31, 2016	$ (181,085)	$ 0	$ 20,887	$ (201,972)	$ 23,848	$ 43,616	$ 34,382	$ 19,469	$ 56,757
Beginning balance (in shares) at Dec. 31, 2016		2,082,053			12,618,279	13,801,318	8,558,686	5,037,784	60
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Series D at fair value for cash, net of issuance costs of $75									$ 7,782
Issuance of stock (in shares)									20
Accretion and payment of Series D dividends	(4,017)		(4,017)						$ 4,017
Stock-based compensation	861		861
Net loss	(105,305)			(105,305)
Ending balance at Dec. 31, 2017	(289,546)	$ 0	17,731	(307,277)	$ 23,848	$ 43,616	$ 34,382	$ 19,469	$ 68,556
Ending balance (in shares) at Dec. 31, 2017		2,082,053			12,618,279	13,801,318	8,558,686	5,037,784	80
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of convertible preferred stock into Private Evofem common stock, excluding Series D	121,315	$ 0	121,315		$ (23,848)	$ (43,616)	$ (34,382)	$ (19,469)
Conversion of convertible preferred stock into Private Evofem common stock, excluding Series D (in shares)		(1,027,079)			(12,618,279)	(13,801,318)	(8,558,686)	(5,037,784)
Issuance of stock (in shares)											3,968,473			1,614,289
Issuance of stock										$ 47,920	$ 1	$ 47,919	$ 20,000		$ 20,000
Cancellation of restricted stock awards		$ 0	0
Cancellation of restricted stock awards (in shares)		(122,149)
Accretion and payment of Series D dividends	(223)		(66)	(157)					$ 66
Conversion of Series D dividends and Series D	5,226	$ 1	5,225						$ (5,226)
Conversion of Series D dividends and Series D (in shares)		(6,878,989)							(80)
Reclassification of Series D 2X liquidation preference upon conversion of Series D	80,000		80,000
Deemed contribution upon conversion of Series D	49,334		49,334						$ (49,334)
Issuance of common stock and WIM Warrants	14,062		14,062						(14,062)
Issuance of common stock and WIM Warrants (in shares)		3
Record pre-merger Neothetics' stockholders' equity and elimination of Neothetics' historical accumulated deficit (in shares)		2,308,430
Record pre-merger Neothetics' stockholders' equity and elimination of Neothetics' historical accumulated deficit	1,946		1,946
Issuance of common stock, pre-funded warrants and common warrants in connection with the Offering, net of underwriting discounts, commissions and offering costs (in shares)																	7,436,171
Issuance of common stock, pre-funded warrants and common warrants in connection with the Offering, net of underwriting discounts, commissions and offering costs																$ 36,030	$ 1	$ 36,029
Issuance of common stock - exercise of stock options	42		42
Issuance of common stock- exercise of stock options (in shares)		6,173
Restricted stock awards/units issued		1,305,399
Shares withheld to cover taxes related to vesting of restricted stock awards (in shares)		(637,662)
Shares withheld to cover taxes related to vesting of restricted stock awards	(1,592)		(1,592)
Stock-based compensation	17,842		17,842
Net loss	(125,712)			(125,712)
Ending balance at Dec. 31, 2018	$ (23,356)	$ 3	$ 409,787	$ (433,146)	$ 0	$ 0	$ 0	$ 0	$ 0
Ending balance (in shares) at Dec. 31, 2018		25,867,248			0	0	0	0	0

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Stock issuance costs	$ 713
Series D Convertible Preferred Stock | Preferred Stock
Stock issuance costs	$ 75

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (125,712)	$ (105,305)
Adjustments to reconcile net loss to net cash, cash equivalents and restricted cash used in operating activities:
Loss on issuance of warrants	47,920	0
Loss on issuance of Series D redeemable convertible preferred stock	0	8,522
Change in fair value of Series D 2X liquidation preference	130	61,175
Stock-based compensation	17,842	861
Depreciation	262	244
Changes in operating assets and liabilities:
Prepaid and other assets	(11)	145
Accounts payable	3,799	7,052
Accrued expenses and other liabilities	(795)	7,319
Accrued compensation	307	775
Deferred rent, net of current portion	(242)	(30)
Net cash, cash equivalents and restricted cash used in operating activities	(56,500)	(19,242)
Cash flows from investing activities:
Purchases of property and equipment	(7)	(6)
Proceeds from sale of Softcup line of business	250	250
Cash acquired in connection with the Merger	1,900	0
Net cash, cash equivalents and restricted cash provided by investing activities	2,143	244
Cash flows from financing activities:
Proceeds from issuance of Series D redeemable convertible preferred stock, net of issuance costs	0	9,925
Proceeds from issuance of common stock - private placement	20,000	0
Proceeds from issuance of common stock, pre-funded warrants and common warrants in connection with the Offering, net of underwriting discounts and commissions	37,542	0
Proceeds from issuance of common stock - exercise of stock options	42	0
Payment of cash dividends for Series D redeemable convertible preferred stock	(157)	0
Cash paid for offering costs	(1,418)	(713)
Payments of tax withholdings related to vesting of restricted stock awards	(1,592)	0
Net cash, cash equivalents and restricted cash provided by financing activities	54,417	9,212
Net change in cash, cash equivalents and restricted cash	60	(9,786)
Cash, cash equivalents and restricted cash, beginning of period	1,701	11,487
Cash, cash equivalents and restricted cash, end of period	1,761	1,701
Cash paid for interest	0	15
Cash paid for taxes	2	3
Supplemental disclosure of noncash investing and financing activities:
Issuance of Series D liquidation preference	0	10,665
Net assets acquired in connection with the Merger	46	0
Public offering costs included in accounts payable and accrued expenses	94	137
Issuance of Promissory Note	4,010	0
Convertible Preferred Stock
Supplemental disclosure of noncash investing and financing activities:
Conversion of preferred stock	121,315	0
Series D Convertible Preferred Stock
Supplemental disclosure of noncash investing and financing activities:
Conversion of preferred stock	68,622	0
Series D 2X liquidation preference
Supplemental disclosure of noncash investing and financing activities:
Conversion of preferred stock	$ 80,000	$ 0

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Merger On January 17, 2018, Neothetics, Inc., a Delaware corporation (Neothetics), now known as Evofem Biosciences, Inc. (the Company), completed its merger (the Merger) with privately-held Evofem Biosciences Operations, Inc. (Private Evofem), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated October 17, 2017 (the Merger Agreement), whereby Nobelli Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Neothetics, merged with and into Private Evofem, with Private Evofem surviving as Neothetics’ wholly-owned subsidiary. In connection with the Merger, Neothetics filed a certificate of amendment to the amended and restated certificate of incorporation to, among other things, affect a 6 :1 reverse stock split of its common stock (the Reverse Stock Split) and change its name from “Neothetics, Inc.” to “Evofem Biosciences, Inc.” Both the name change and the Reverse Stock Split were effective on January 17, 2018 (the Closing Date). Shares of the Company's common stock commenced trading on The Nasdaq Capital Market under the ticker symbol “EVFM” as of January 18, 2018. See discussions of the transactions in connection with the Merger at Note 3- Merger and Related Transactions. Evofem Biosciences, Inc.’s operations include those of its wholly-owned subsidiaries, Evofem Biosciences Operations, Inc., a Delaware corporation, Evofem Inc., a Delaware corporation, Evofem North America, Inc., a Delaware corporation (ENA), Evofem Limited, LLC, a Delaware limited liability company and Evofem Ltd., a limited company registered in England and Wales and those of its partially owned subsidiary, Evolution Pharma, a Dutch limited partnership (EP) with 99% of the outstanding partnership interests held by Evofem Inc. and 1% of the outstanding partnership interests held by Evofem Limited, LLC. Evofem Limited, LLC and Evofem Ltd. are currently inactive. Unless otherwise noted, (i) references in this report to “Evofem” and the “Company” refer to Evofem Biosciences, Inc. and its subsidiaries following the closing of the Merger on the Closing Date, (ii) references to “Private Evofem” refer to Evofem Biosciences Operations, Inc. and its subsidiaries prior to the closing the Merger on the Closing Date, (iii) references to “Neothetics” refer to Neothetics, Inc. and its subsidiaries prior to the closing of the Merger on the Closing Date, and (iv) references to share amounts, figures (other than exchange ratios) and other information have been adjusted to reflect the Reverse Stock Split. Description of Business Evofem is a San Diego-based clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health. Evofem exists to advance the lives of women by developing innovative solutions, such as woman-controlled contraception and potential protection from certain sexually transmitted infections (STIs). The Company is leveraging its proprietary Multi-purpose Vaginal pH Regulator TM (MVP-R) platform to develop product candidates for multiple potential indications, including prevention of pregnancy, prevention of STIs, and reduction of recurrent bacterial vaginosis (BV). Evofem's MVP-Rs are acid-buffering bioadhesive vaginal gels designed to regulate vaginal pH within the normal range of 3.5 to 4.5. This vaginal pH range is inhospitable to spermatozoa, as well as certain viral and bacterial pathogens associated with STIs, but is integral to the survival of healthy bacteria in the vagina. Evofem’s lead MVP-R product candidate, Amphora ® (L-lactic acid, citric acid, and potassium bitartrate), is a non-hormonal, on demand, woman-controlled vaginal gel. Its second Phase 3 clinical trial for prevention of pregnancy had the last patient exit the study in November 2018 and positive top-line data released in December 2018. It is also currently being evaluated in a Phase 2b trial for the prevention of urogenital transmission of chlamydia and gonorrhea in women. Evofem’s pipeline also includes an MVP-R product candidate for reduction of recurrent BV. The Company is planning a Phase 2 clinical trial for this indication, building on favorable Phase 1 trial results. Basis of Presentation and Principles of Consolidation Since Private Evofem was determined to be the accounting acquirer in connection with the Merger, it recorded Neothetics’ assets and liabilities at fair value as of the Closing Date. Therefore, for periods prior to the Merger, the consolidated financial statements were prepared on a stand-alone basis for Private Evofem and did not include the combined entities' financial position. Subsequent to the Merger, the consolidated financial statements as of and for the year ended December 31, 2018 from the Closing Date included Neothetics' assets and liabilities. The Company prepared the consolidated financial statements in accordance with accounting principles generally accepted in the U.S. (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) related to annual reports on Form 10-K. The Company’s financial statements are presented on a consolidated basis, which include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. Risks, Uncertainties and Going Concern The financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities, in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. The Company’s principal operations have been related to research and development (R&D), including development of Amphora as well as raising capital, recruiting personnel and establishing a corporate infrastructure. The Company has no revenues and, as such, has incurred operating losses and negative cash flows from operating activities since inception, and has negative working capital and a net capital deficiency at December 31, 2018. As described in Note 9- Public Offering , the Company received proceeds of approximately $36.0 million , net of underwriting discounts and commissions and estimated offering costs, from a public offering that closed on May 24, 2018. As of December 31, 2018 , the Company had cash and cash equivalents of $1.3 million , working capital deficit of $24.9 million and an accumulated deficit of $433.1 million . The Company is subject to risks common to other life science companies in the development stage including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with U.S. Food and Drug Administration (FDA) and other government regulations. If the Company does not successfully commercialize any product candidates, it will be unable to generate recurring product revenue or achieve profitability. Management's plans to meet its short- and long-term operating cash flow requirements include obtaining additional funding, such as through the issuance of its common stock, from other equity or debt financings, or through collaborations or partnerships with other companies. The Company anticipates it will continue to incur net losses for the foreseeable future and incur additional costs associated with being a public company. R&D expenses are expected to decrease for the foreseeable future due to the completion of the clinical phase of confirmatory Phase 3 clinical trial for Amphora for prevention of pregnancy. According to management estimates, liquidity resources as of December 31, 2018 are not sufficient to maintain its planned level of operations for the 12 months from the date of issuance of the financial statements. These circumstances and the uncertainties associated with the Company's ability to (i) obtain additional equity financing on terms that are favorable to Evofem, (ii) enter into collaborative agreements with strategic partners and (iii) succeed in its future operations, raise substantial doubt about the Company's ability to continue as a going concern. If the Company is not able to obtain the required funding in the near term, through equity financings or other means, or is unable to obtain funding on terms favorable to the Company, this will have a material adverse effect on its operations and strategic development plan for future growth. If the Company cannot successfully raise additional funding and implement its strategic development plan, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, suspend or curtail planned programs or cease operations entirely. Any of these could materially and adversely affect its liquidity, financial condition and business prospects and the Company would not be able to continue as a going concern. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on the financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto. S ignificant estimates affecting amounts reported or disclosed in the consolidated financial statements include, but not limited to, the measurement of the Series D 2X liquidation preference, assumptions used in estimating the fair value of warrants issued in connection with the Merger, the useful lives of property and equipment, the recoverability of long-lived assets, preclinical and clinical trial accruals, assumptions used in estimating the fair value of stock-based compensation expense and other contingencies. The Company’s assumptions regarding the measurement of the Series D 2X liquidation preference and stock-based compensation are more fully described in Note 5 — Fair Value of Financial Instruments and Note 11 — Stock-based Compensation, respectively. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions. Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, who is the Chief Executive Offer (CEO) of the Company, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking and time deposit accounts are maintained in federally insured financial institutions in excess of federally insured limits. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets. The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held. Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consists of readily available cash in checking and money market accounts. Restricted cash consists of cash held in monthly time deposit accounts, which are collateral for the Company’s credit cards and facility leases. The following table provides a reconciliation of cash, cash equivalents and restricted cash, reported within the consolidated statements of cash flows (in thousands): Years Ended December 31, 2018 2017 Cash and cash equivalents $ 1,330 $ 1,211 Restricted cash 431 490 Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows $ 1,761 $ 1,701 Fair Value of Financial Instruments The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. The Company applies fair value accounting for all assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. The valuation of assets and liabilities are subject to fair value measurements using a three-tiered approach and fair value measurement is classified and disclosed by the Company in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, restricted cash, accounts payable, note payable, accrued expenses and accrued compensation approximate their fair values due to their short-term nature. As of December 31, 2018 and 2017 , based on the borrowing rate currently available to the Company for loans with similar terms, which is considered a Level 2 input, the Company believes the fair value of the Flex Note (as defined below) approximates its carrying value. Property and Equipment Property and equipment generally consist of research equipment, computer equipment and software and office furniture, and are recorded at cost and depreciated over the estimated useful lives of the assets (generally three to five years ) using the straight-line method. Leasehold improvements are stated at cost and are amortized on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged to expense as incurred and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheets and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized. Impairment of Long-lived Assets The Company reviews property and equipment for impairment on an annual basis and whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset or asset group are less than its carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset or asset group exceeds its fair value. While the Company’s current and historical operating losses and negative cash flows are possible indicators of impairment, management believes that future cash flows to be generated by these assets support the carrying value of its long-lived assets and, accordingly, did not recognize any impairment losses during the years ended December 31, 2018 and 2017 . Clinical Trial Accruals As part of the process of preparing our financial statements, we are required to estimate expenses resulting from our obligations under contracts with vendors, clinical research organizations (CROs), consultants and under clinical site agreements relating to conducting our clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company's objective is to reflect the appropriate clinical trial expenses in our consolidated financial statements by recording those expenses in the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by patient progression and the timing of various aspects of the trial. Management determines accrual estimates through financial models and discussions with applicable personnel and outside service providers as to the progress of clinical trials. During a clinical trial, the Company adjusts the clinical expense recognition if actual results differ from its estimates. The Company makes estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company’s clinical trial accruals are partially dependent upon accurate reporting by CROs and other third-party vendors. Although the Company does not expect its estimates to differ materially from actual amounts incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low for any period. For the years ended December 31, 2018 and 2017 there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials. Fair Value of Series D and Series D 2X Liquidation Preference Prior to completion of the Merger, the Company valued its Series D redeemable convertible preferred stock (Series D) and Series D 2X liquidation preference in accordance with Accounting Standards Codification (ASC) No. 815 — Derivatives and Hedging , using a probability-weighted expected return model (PWERM), which is sensitive to changes in assumptions regarding the timing of additional financings, potential exit scenarios and revisions in our financial forecast. Changes in any one of the assumptions could have had a material impact on the estimated fair value of the Series D and Series D 2X liquidation preference. Management used the most reliably available information at each issuance of Series D to determine the fair value of the Series D and at each valuation date to determine the fair value of the Series D 2X liquidation preference. Due to the nature of the assumptions and the sensitive nature of the PWERM, management could not reliably provide sensitivity analysis around the impact of changes in assumptions utilized in the PWERM used to estimate the fair value of the Series D and Series D 2X liquidation preference. Convertible Preferred Stock Prior to the Merger, the Company’s Series A, Series B, Series C-1, Series C convertible preferred stock and Series D were classified as temporary equity instead of stockholders’ deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities, as the shares were conditionally redeemable at the holder’s option and upon certain change in control events that are outside the Company’s control, including liquidation, sale, or transfer of control of the Company. Upon completion of the Merger, the Company's Series A, Series B, Series C-1, Series C convertible preferred stock and Series D were converted into common stock. Fair Value of Warrants The fair value of the WIM and Invesco Warrants (as defined below) issued in connection with the Merger were determined using the Black-Scholes-Merton (BSM) option-pricing model based on the applicable assumptions, which include the warrants exercise price, time to expiration, expected volatility of our peer group, risk-free interest rate and expected dividend. Research and Development R&D expenses include the costs associated with the Company’s R&D activities, including, but not limited to, payroll and personnel-related expenses, stock-based compensation expense, materials, laboratory supplies, clinical studies and outside services. R&D costs are expensed as incurred, except when accounting for nonrefundable advance payments for goods or services not yet received. These payments, if any, are capitalized at the time of payment and expensed as the related goods are delivered or the services are performed. Patent Expenses The Company expenses all costs incurred relating to patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated statements of operations. Stock-based Compensation Stock-based compensation expense for equity instruments issued to employees, nonemployee directors and consultants is measured based on estimating the fair value of each stock option on the date of grant using the BSM option-pricing model. Expensing The following table summarizes the Company’s stock-based awards expensing policies for employees and nonemployees: Employees and Nonemployee Consultants After Adopting ASU 2018-07 Nonemployee Consultants Prior to Adopting ASU 2018-07 Service only condition Straight-line based on the grant date fair value Re-value at each reporting date through the service commitment date Performance criterion is probable of being met: Service criterion is complete Recognize the grant date fair value of the award(s) once the performance criterion is considered probable of occurrence Re-value the award(s) once the performance criterion is considered probable of occurrence and recognize expense for the then fair value of the award(s) Service criterion is not complete Expense using an accelerated multiple-option approach (1) over the remaining requisite service period Same as for employees, except the award will be marked-to-market through the performance commitment date Performance criterion is not probable of being met and: Is not tied to the successful completion of an initial public offering of the Company’s common stock (IPO) No expense recognition is required until the performance criterion is considered probable at which point expense is recognized using an accelerated multiple-option approach Same as for employees, except the award will be marked-to-market through the performance commitment date Is tied to the successful completion of an IPO by the Company Upon closing of an IPO by the Company, recognize the grant date fair value of the award(s) Same as for employees, except expense is recognized based upon the fair value of the Company’s common stock sold in the IPO ________________ (1) The accelerated multiple-option approach results in compensation expense being recognized for each separately vesting tranche of the award as though the award was in substance multiple awards and, therefore, results in accelerated expense recognition during the earlier vesting periods. Determining Fair Value of Stock Options Prior to the Merger, the fair value of the shares of the Company’s common stock underlying its stock-based awards was estimated on each grant date by the Company’s board of directors. To determine the fair value of the common stock underlying option grants, the Company’s board of directors considered, among other things, valuations of the Company’s common stock prepared by an unrelated valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Given the absence of a public trading market for its common stock prior to completion of the Merger, the board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock, including the Company’s stage of development; progress of the Company’s R&D efforts; the Company’s operating and financial performance, including levels of available capital resources; the rights, preferences and privileges of the Company’s convertible preferred stock relative to those of its common stock; sales of the Company’s convertible preferred stock; the valuation of publicly traded companies in its industry, equity market conditions affecting comparable public companies and the lack of marketability of the Company’s common stock. The Company obtained valuations on at least an annual basis or when it determined that significant value generating or diminishing internal and/or external events had occurred which would significantly increase or decrease the fair value of the common stock underlying its stock-based awards. Post the Merger, the fair value of our common stock will be equal to the closing price of our stock. For purposes of re-measuring the Company’s consultant stock options, the Company utilized the concluded fair values for the Company’s common stock underlying the stock options as aforementioned prior to the Merger or the closing price at each reporting date post the Merger to recognize estimated consultant stock-based compensation expense using the BSM at each reporting date. Forfeitures The Company adopted ASU No. 2016-09 Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU No. 2016-09) in fiscal year 2016, under which the Company made a one-time policy election to record forfeitures when they occur. Performance-based Awards For performance-based restricted stock awards (RSAs) (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual milestone under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met. Income Taxes The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made. Net Loss Per Share Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented. Potentially dilutive securities excluded from the calculation of diluted net loss per share are summarized in the table below. For the year ended December 31, 2018, the shares in the table also included 1,013,375 shares of options granted out of the share reserve increase approved by the board of directors under the Amended and Restated 2014 Plan (as defined below) on November 28, 2018, and are subject to the Company obtaining the requisite stockholder approval (the Contingent Options) at the 2019 annual meeting. For the year ended December 31, 2017, the shares in the table have been adjusted to reflect the conversion of Series A, B, C-1, and C convertible preferred stock and Series D as fully described in Note 8- Convertible Preferred Stock , and the Reverse Stock Split. Years Ended December 31, 2018 2017 Convertible preferred stock — 1,027,079 Series D redeemable convertible preferred stock — 6,878,986 Unvested restricted common stock subject to repurchase — 122,149 Unvested restricted stock units — 2,566 Options to purchase common stock 5,767,627 160,248 Warrants to purchase common stock 4,775,886 — Total 10,543,513 8,191,028 Recently Adopted Accounting Pronouncements The Company qualifies as an “emerging growth company” (EGC) pursuant to the provisions of the Jumpstart Our Business Startups (JOBS) Act from the fiscal year 2014 to 2018. Section 7(a)(2)(B) of the Securities Act of 1933, as amended, permits EGCs to defer compliance with new or revised accounting standards until non-issuers are required to comply with such standards. However, the Company elected not to take advantage of the extended transition period for implementation of new or revised financial accounting standards, and as a result, the Company will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU No. 2014-09), which amends the existing accounting standards for revenue recognition. ASU No. 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. The new standard as amended by ASU No. 2015-14 ( Revenue from Contracts with Customers (Topic 606): Deferral of The Effective Date) , ASU No. 2016-10 ( Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligation and Licensing), and ASU No. 2016-12 ( Revenue from Contracts with Customers (Topic 606): Narrow-scope Improvements and Practical Expedients) was effective for the Company beginning January 1, 2018. The Company adopted the new standard using the full retrospective approach, which did not have an impact on the Company’s financial position or results of operations as the Company is pre-revenue and does not anticipate generating any significant revenue prior to 2020. In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting (ASU No. 2017-09), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. ASU No. 2017-09 was effective for the Company beginning January 1, 2018. The adoption of this new standard did not have a material impact on the Company’s financial position or results of operations. In June 2018, the FASB issued ASU No. 2018-07, Compensation- Stock Compensation (Topic 718 ) (ASU No. 2018-07), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees that are currently covered under Accounting Standards Codification (ASC) 505-50 , Equity-Based Payments to Non-employees. ASU No. 2018-07 will be effective for the Company beginning January 1, 2019 and early adoption is permitted. The Company adopted this new standard on September 30, 2018 using a modified retrospective transition method, under which the Company valued the equity awards to nonemployees as of September 30, 2018; any expense recorded for the awards in the future will be based on this value. There was no cumulative effect of the change on retained earnings. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842 ) (ASU No. 2016-02), which changes the presentation of assets and liabilities relating to leases. The core principle of ASU No. 2016-02 is that a lessee should recognize the assets and liabilities that arise from leases. The new standard as amended by ASU No. 2018-01 ( Leases (Topic 842 ): Land Easement Practical Expedient for Transition to Topic 842 ), ASU No. 2018-10 ( Codification Improvements to Topic 842, Leases ), and ASU No. 2018-11 ( Leases (Topic 842): Targeted Improvements ) (ASC No. 2018-11) was effective for the Company beginning January 1, 2019. This new standard is required to be adopted using a modified retrospective approach with certain available transitional practical expedients. The ASU No. 2018-11 issued in July 2018 allows for the adoption of the new standard to be applied at the adoption date as opposed to at the beginning of the earliest year presented. On January 1, 2019, the Company adopted this new standard under the provisions allowed under ASU 2018-11. Based on the Company's evaluation of impact on its financial statements, the Company currently expects to record approximately $0.8 million right-of-use assets and $1.0 million lease liabilities for all its active leases as of the adoption date in the consolidated balance sheets, and no material impact on its consolidated results of operations or cash flows. Recently Issued Accounting Pronouncements — Not Yet Adopted In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820 ) (ASU No. 2018-13), which removes, modifies and adds certain disclosure requirements on fair value measurements in Topic 820. ASU No. 2018-13 will be effective for the Company beginning January 1, 2020. Early adoption is permitted. The Company is in the process of evaluating the impact of this standard on disclosures in its consolidated financial statements.

Merger and Related Transactions

Merger and Related Transactions	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Merger and Related Transactions	Merger and Related Transactions As described in Note 1- Description of Business and Basis of Presentation, Private Evofem merged with the Company effective on the Closing Date. The Merger was accounted for as a reverse recapitalization with Private Evofem treated as the accounting acquirer pursuant to ASC 805- Business Combinations. Under reverse recapitalization accounting, the accounting acquirer shall measure the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at their acquisition-date fair values. The following transactions were completed with the Merger and recorded by the Company: • Recorded Neothetics' assets and liabilities at fair value as of the Closing Date, including $1.9 million cash and cash equivalents, $0.5 million prepaids and other current assets, $0.4 million current and noncurrent liabilities and $1.9 million common stock (Neothetics had 2,308,430 shares of common stock outstanding as of the Closing Date on a post-split basis at par value of $0.0001 per share) and additional paid-in capital (including the reclassification of Neothetics' historical accumulated deficit into additional paid-in capital); • Converted each share of Private Evofem’s capital stock including its Series A convertible preferred stock, Series B convertible preferred stock, Series C-1 convertible preferred stock and Series C convertible preferred stock into the Company's common stock on a one -for-one basis effecting the merger exchange ratio of 0.1540 , subject to adjustment for the Reverse Stock Split (the Exchange Ratio) and the Reverse Stock Split for an aggregate of 1,027,079 shares. Upon such conversion, reclassified the net proceeds from issuance of these preferred stocks to common stock at par value and additional paid-in capital, net of par value; • Cancelled 122,149 shares of unvested restricted common stock; • Issued warrants for the purchase up to an aggregate of 3,980,437 shares of common stock to funds affiliated with Invesco Ltd. (the Invesco Warrants), which were immediately net exercised on a cashless basis for 3,968,473 shares of common stock; • Converted 80 shares of Private Evofem’s Series D into 6,878,989 shares of the Company's common stock, including: i. Adjustment for the final change in fair value of Private Evofem’s Series D 2X liquidation preference; ii. Redemption of the Series D 2X liquidation preference upon conversion; iii. Private Evofem’s Series D Warrant Rights (as defined below) were assumed by the Company and exchanged for three shares of the Company's common stock and warrants for the purchase of 2,000,000 shares of the Company's common stock (the WIM Warrants). The Company recorded the fair value of the WIM Warrants and related capital contribution upon issuance of the WIM Warrants; and iv. Recording cash dividends between January 6, 2018 and the Closing Date, which was paid upon closing of the Merger to Woodford Investment Management Ltd (WIM). • The Company affected the Reverse Stock Split, and thus the Company adjusted common stock and additional paid-in capital associated with shares issued in connection with the Merger due to the 6:1 reverse stock split, which the Company has affected in the amounts described within this footnote; • The Company assumed options to purchase Private Evofem common stock that were outstanding and unexercised as of immediately prior to the Merger (the Private Evofem Plan Options). The Private Evofem Plan Options, were converted into options to purchase 159,325 shares of our common stock, as adjusted for the Exchange Ratio and Reverse Stock Split, at a weighted average price of $56.72 ; and • Sold 1,614,289 shares of the Company's common stock in a private placement for gross proceeds of $20.0 million .

Balance Sheet Details

Balance Sheet Details	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Details	Balance Sheet Details Prepaid and Other Current Assets Prepaid and other current assets consist of the following (in thousands): Years Ended December 31, 2018 2017 Flex note receivable (1) $ 250 $ 250 Insurance 199 96 Clinical supplies 62 119 Rent 66 63 Other receivable from related parties 11 17 Other 129 108 Total $ 717 $ 653 _______________________ (1) In June 2016, Private Evofem’s board of directors committed to a plan to sell its Softcup line of business (Softcup) and re-direct its available cash resources to further develop Amphora. In July 2016, the Company entered into an Asset Purchase Agreement with The Flex Company (Flex), whereby Flex would acquire certain assets and assume certain liabilities associated with Softcup. Total consideration for the Softcup sale was $1.9 million , with $0.6 million received in cash at closing and the remaining $1.3 million due and payable under a note in favor of the Company (the Flex Note) through January 1, 2021 (the Maturity Date). The Flex Note bears simple interest at a rate of 5.0% per annum on the remaining principal amount outstanding. An annual principal payment of approximately $0.3 million and the annual accrued and unpaid interest are payable each January 1, beginning in 2017 through the Maturity Date. The Flex Note is secured by the Softcup assets and has been recorded at present value. The Company’s incremental borrowing rate and the stated interest rate of the Flex Note are materially consistent. Property and Equipment, Net Property and equipment, net, consists of the following (in thousands): Years Ended December 31, Useful Life 2018 2017 Research equipment 5 years $ 639 $ 639 Computer equipment and software 3 years 13 6 Office furniture 5 years 205 205 Leasehold improvements 5 years or less 340 340 1,197 1,190 Less: accumulated depreciation and amortization (604 ) (342 ) Total, net $ 593 $ 848 Depreciation expense was $0.3 million and $0.2 million for the years ended December 31, 2018 and 2017, respectively. Other Noncurrent Assets Other noncurrent assets consist of the following (in thousands): Years Ended December 31, 2018 2017 Flex note receivable, net of current portion $ 500 $ 750 Prepaid Directors & Officers insurance 439 — Total $ 939 $ 750 Note Payable On December 5, 2018, the Company entered into a promissory note (Note) with our CRO for AMPOWER, where the Company agreed to pay the CRO on invoiced amounts totaling approximately $4.0 million for clinical trial related services and has a due date of February 15, 2019. Any matured and unpaid amounts pursuant to this Note bears an annual interest rate of the lesser of 1% per month or the maximum amount permitted by the Laws of the State of Massachusetts. In late February 2019, the Company amended the Note, which extended the due date to April 15, 2019. All other terms and conditions under the initial Note remain the same. If the Company defaults on the payment of this Note, the CRO may declare the unpaid principal balance and earned interest on this Note immediately due. Accrued Expenses Accrued expenses consist of the following (in thousands): Years Ended December 31, 2018 2017 Clinical studies $ 9,153 $ 8,789 Sublicense fees 1,117 2,000 Accrued interest on unpaid sublicense fees 174 76 Legal and other professional fees 549 727 Accrued franchise tax 188 12 Public offering costs 127 135 Board of directors’ fees and related expenses 67 247 Other 138 100 Total $ 11,513 $ 12,086

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair values of the Company’s assets and liabilities, including the money market fund, Flex Note receivable and Series D 2X liquidation preference, measured on a recurring basis are summarized in the following tables, as applicable (in thousands): December 31, 2018 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Money market fund (1) $ 154 $ 154 $ — $ — Flex note receivable 750 — 750 — Total assets $ 904 $ 154 $ 750 $ — _______________________ (1) Included as a component of cash and cash equivalents on the accompanying consolidated balance sheet. December 31, 2017 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Flex note receivable $ 1,000 $ — $ 1,000 $ — Series D 2X liquidation preference (79,870 ) — — (79,870 ) Total assets (liabilities) $ (78,870 ) $ — $ 1,000 $ (79,870 ) Series D 2X liquidation preference is stated at fair value and is considered a Level 3 input because the fair value measurement is based, in part, on significant inputs not observed in the market. The Company determined the fair value of Series D 2X liquidation preference as described below. The following table summarizes the changes in Level 3 financial liabilities measured at fair value on a recurring basis for the year ended December 31, 2018 and 2017 (in thousands). Series D 2X Liquidation Preference Liability Balance at December 31, 2016 $ 8,030 Issuance of Series D 2X liquidation preference 10,665 Change in fair value of Series D 2X liquidation preference 61,175 Balance at December 31, 2017 $ 79,870 Change in fair value of Series D 2X liquidation preference 130 Redemption of Series D 2X liquidation preference upon conversion of Series D (80,000 ) Balance at December 31, 2018 $ — Series D 2X Liquidation Preference As described in the Note 2- Summary of Significant Accounting Policies , the Company’s issuance of Series D resulted in the identification of an embedded derivative that required bifurcation and liability accounting at fair value. See the Series D Redeemable Convertible Preferred Stock discussion in Note 8 — Convertible Preferred Stock for the terms of the Series D. To determine the fair value of the Company’s Series D 2X Liquidation Preference associated with the August and November 2017 issuances of 15 shares and 5 shares, respectively, of Series D in connection with the Series D amendment (see the Series D discussion in Note 8 — Convertible Preferred Stock ), the Company utilized a hybrid valuation model that considers the probability of achieving certain exit scenarios, the Company’s cost of capital, the estimated period the Series D 2X Liquidation Preference would be outstanding, consideration received for the instrument with the Series D 2X Liquidation Preference and at what price and changes, if any, in the fair value of the underlying instrument to the Series D 2X Liquidation Preference. The valuations resulted in a concluded fair value of the Series D 2X Liquidation Preference at issuance of $2.8 million and $7.9 million for the 15 and 5 shares, respectively, of Series D in connection with the Series D amendment. To determine the change in fair value of the Series D 2X liquidation preference, the Company utilized a hybrid valuation model that considers the probability of achieving certain exit scenarios, the Company’s cost of capital, the estimated period the Series D 2X liquidation preference would be outstanding, consideration received for the instrument with the Series D 2X liquidation preference and at what price and changes, if any, in the fair value of the underlying instrument to the Series D 2X liquidation preference. At December 31, 2017, the most significant assumption was the probability of occurrence, which was concluded to be high, and as a result the fair value as of December 31, 2017 approximated the final redemption value. In connection with the Merger, Private Evofem converted 80 shares of Series D into the Company's common stock. The valuations resulted in a concluded fair value of the Series D 2X liquidation preference of $80.0 million as of the Closing Date based on the hybrid valuation model, which was reclassified from a Series D 2X liquidation preference to additional paid-in capital upon the conversion into the Company' common stock. The change in fair value of the Series D 2X liquidation preference for the years ended December 31, 2018 and 2017 was $0.1 million and $61.2 million , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases In November 2009, Private Evofem entered into a lease for office space under a noncancelable lease agreement that expired in March 2017 (the UTC Lease), as amended. Through January 2015, Private Evofem shared this office space with Cosmederm Biosciences, Inc. (Cosmederm) when Private Evofem assigned its rights and obligations under the UTC Lease to Cosmederm. Effective February 27, 2017, Private Evofem entered into a lease termination agreement (the UTC Lease Termination) with Cosmederm and the landlord for the UTC Lease. In March 2017, Private Evofem paid $55,000 of an early termination fee directly to Cosmederm who remitted the fee to the landlord, and derecognized the security deposit receivable from the landlord and payable to Cosmederm. Upon execution of the UTC Lease Termination, Private Evofem was relieved of all obligations under the UTC Lease. Effective January 30, 2015, Private Evofem entered into a sublease for office space under a noncancelable lease agreement that expires in March 2020 (the 2015 Lease). The sublease provides for two renewal periods of five years each, but the sub-lessor is not expected to renew its lease. In lieu of paying a security deposit directly to the sub-lessor, the Company maintains a time deposit in favor of the sub-lessor (the Deposit), which is included in restricted cash in the consolidated balance sheets. During months 13 through 58 of the 2015 Lease term, subject to certain restrictions, approximately $5,000 of the Deposit may be released each month through November 2019 and approximately $66,000 of the Deposit may be released each month between December 2019 and March 2020. As of December 31, 2018 and 2017, restricted cash maintained as collateral for the Company’s Deposit was $0.3 million and $0.4 million , respectively. Concurrent with the execution of the 2015 Lease, Private Evofem entered into a sublease with WomanCare Global Trading, Inc. (WCGT) whereby WCGT agreed to sublease approximately 25% (subject to annual adjustment), as amended, of the Company’s office space (the WCG Sublease). The Company remains the primary obligor under the WCG Sublease and records all sublease income as a reduction of rent expense in the consolidated statements of operations. WCGT paid an initial security deposit of approximately $0.3 million (the WCG Security Deposit). Effective April 1, 2018, the WCG Sublease was reassigned from WCGT to WCG Cares, whereby WCG Cares agreed to pay the Company 20% of the overall lease payment under the 2015 Lease. All terms and conditions remain the same as the original WCG Sublease. As of December 31, 2017 , the WCG Security Deposit totaled approximately $0.2 million , which was included in accrued expenses and other noncurrent liabilities in the consolidated balance sheet and was repaid to WCGT in June 2018. There were $0.1 million and $0.2 million of sublease payments received pursuant to the WCG Sublease during the years ended December 31, 2018 and 2017, respectively. The Company terminated the WCG Sublease in the fourth quarter of 2018. On January 20, 2015, Neothetics entered into a non-cancelable operating lease with LJ Gateway Office LLC (LJ Gateway Lease) for its facilities, which expires in March 2020. In connection with the LJ Gateway Lease, Neothetics issued a stand-by letter of credit in lieu of a security deposit. On January 31, 2017, Neothetics entered into an Eleventh Amendment to the LJ Gateway Lease (the Lease Amendment), which provided Neothetics with additional office space located at Suite No. 250. Concurrent with the Lease Amendment, Neothetics entered into a sublease providing for the sublease of additional office space (Suite 270). Upon the occurrence of the sublessee retaining possession of the original premises in February 2017, the sublessee received rent abatement for months one, three, and four as well as a discount of 50% off the base rent for months five through nine. The sublessee paid Neothetics a base rent of approximately $28,000 for the second month’s rent and $30,000 security deposit. The base rent will increase by three percent on each annual anniversary. The Company has recorded the rental income collected or accrued under the sublease as a reduction of rent expense. In December 2017, Neothetics entered into the Twelfth Amendment to the LJ Gateway Lease, whereby upon the mutual execution and delivery of a new lease between LJ Gateway Office LLC’s affiliate and the sublessee and upon the occurrence of the sublessee vacating their subleased space, LJ Gateway Office LLC and Neothetics agreed that the LJ Gateway Lease with respect to the Suite 270 office space shall be terminated. In June 2018, the LJ Gateway Lease was terminated. Upon termination, the Company repaid the sublessee's approximately $30,000 security deposit. Rent expense was $0.6 million and $0.5 million for the years ended December 31, 2018 and 2017 , respectively. Rent expense is recognized on a straight-line basis over the term of the lease. Accordingly, rent expense recognized in excess of rent paid is accounted for as deferred rent in the consolidated balance sheets, of which the current portion is included in accrued expenses in the consolidated balance sheets. As of December 31, 2018 , future minimum lease commitments under the above mentioned operating leases, together with sublease income, are as follows (in thousands): Operating Leases Year ending December 31, 2019 $ 777 Year ending December 31, 2020 201 Total $ 978 Contingencies From time to time the Company may be involved in various lawsuits, legal proceedings or claims that arise in the ordinary course of business. There were no claims or actions pending against the Company as of December 31, 2018 and 2017, which management believes would have, individually or in the aggregate, a material adverse effect on its business, liquidity, financial position, results of operations or cash flows. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. Intellectual Property Rights In 2014, Private Evofem entered into an amended and restated license agreement with Rush University (the Rush License Agreement) pursuant to which Rush University granted Private Evofem an exclusive, worldwide license of certain patents and know-how, related to its MVP-R technology authorizing Private Evofem to make, distribute and commercialize products and processes for any and all therapeutic, prophylactic and/or diagnostic uses, including, without limitation, use for female vaginal health and/or birth control. The Company may be obligated to pay an earned royalty based upon a percentage of net sales in the range of mid-single digits. Commencing on January 1 of year three after a product has received regulatory approval and has been introduced to market, the Company may become obligated to pay minimum annual royalties, to the extent the earned royalty or sublicensing fees, as applicable, do not exceed the minimum annual royalties. In October 2015, the Company's subsidiaries, ENA and EP entered into separate sublicense agreements (the Sublicenses) with WomanCare Global Trading CIC (WCGCIC) for a contraceptive vaginal ring. In August 2016, ENA, EP and WCGCIC entered into a side letter to modify the timing of the 2016 and 2017 payments due under the Sublicenses. On an aggregate basis, consideration under the Sublicenses consisted of (i) payments or potential payments to the licensor of (a) an upfront payment of $10.0 million , (b) potential regulatory and commercial milestone payments up to $32.0 million , (c) potential royalty payments on net product sales and (d) potential royalty payments on net sales of an equivalent generic product and (ii) $5.0 million in annual sublicense fees through October 1, 2019 to WCGCIC. In December 2016, under the terms of the Sublicenses, ENA and EP provided 90-days written notice of termination of the Sublicenses to WCGCIC, which period concluded on March 28, 2017. As of December 31, 2018 and 2017, the Company had accrued sublicense fees of approximately $1.1 million and $2.0 million , respectively, which are included in accrued expenses in the consolidated balance sheets. The Company is responsible for making interest payments to WomanCare Global International, a non-profit organization registered in England and Wales (WCGI), for unpaid sublicense fees. As of December 31, 2018 and 2017, accrued interest expense on unpaid sublicense fees totaled $0.2 million and $0.1 million , respectively. See Note 7 – Related-party Transactions for a summary of the Company’s transactions with WCGCIC and WCGI and related entities.

Related-party Transactions

Related-party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related-party Transactions	Related-party Transactions Consulting Agreements Effective April 1, 2016, Private Evofem entered into a one -year consulting agreement (the 2016 Consulting Agreement) with Thomas Lynch, the chairman of the Company’s board of directors. Pursuant to the 2016 Consulting Agreement, Mr. Lynch provides consulting services with respect to investor relations and business development activities as requested from time to time. Pursuant to the 2016 Consulting Agreement, Mr. Lynch (i) received compensation of approximately $0.4 million , including $0.1 million related to his board services, (ii) received a stock option for the purchase of 3,850 shares of common stock with an exercise price of $46.36 per share, which vest over a one -year period through March 1, 2017 and (iii) was issued a restricted stock unit (RSU) for the rights to 2,566 shares of common stock. Upon closing of the Merger, Mr. Lynch agreed to cancel all of his unvested RSUs received pursuant to the 2016 Consulting Agreement. See Restricted Stock Units discussion in Note 11 — Stock-based Compensation for the accounting treatment for Mr. Lynch’s RSUs granted in 2016. On July 2, 2018, under the Amended and Restated 2014 Plan (as defined below), the Company issued 75,000 shares of RSUs to Mr. Lynch in consideration for certain consulting services provided to the Company in connection with the 2016 Consulting Agreement. The RSUs were fully vested on the grant date. In August 2017, Private Evofem and Mr. Lynch entered into a two -year consulting agreement (the 2017 Consulting Agreement), which was effective as of April 1, 2017. This 2017 Consulting Agreement provides for (i) annual compensation of $0.4 million , including $0.1 million related to his board services and (ii) a stock option for the purchase of 6,416 shares of common stock that vests quarterly through March 31, 2018, which remained unissued at the time of the Merger. On March 12, 2018, the Company issued a stock option for the purchase of 225,000 shares of the Company's common stock with an exercise price of $7.29 per share in lieu of the unissued stock option pursuant to the 2017 Consulting Agreement, of which 125,000 vested on the grant date and the remaining shares shall vest in a series of twelve successive equal monthly installments upon completion of each additional month of service measured from April 1, 2018. The option was awarded in connection with Mr. Lynch's consulting services for the Company for the fiscal years 2016 to 2018. This option was granted under the Amended and Restated 2014 Plan, which was approved at the Company’s annual meeting held on May 8, 2018. On July 31, 2018, the Company issued additional stock options for the purchase of 85,500 shares of the Company's common stock with an exercise price of $2.10 per share pursuant to the 2017 Consulting Agreement, which vest in a series of 36 successive equal monthly installments upon completion of each additional month of service measured from the grant date. Consulting fees incurred under the 2016 and 2017 Consulting Agreements were approximately $0.3 million for both the years ended December 31, 2018 and 2017. On July 31, 2018, the Compensation Committee, with the authorization of the board of directors, approved a one-time, discretionary cash bonus award to Mr. Lynch in the amount of $50,000 . As of December 31, 2018 and 2017, accrued compensation, excluding board fees, owed to Mr. Lynch was $0.1 million for both periods. Transactions with WCGI and Related Entities From 2009 to 2016, Ms. Saundra Pelletier was the founding CEO of WCGI. In February 2013, Private Evofem and WCGI formed an alliance (the WCGI Alliance) and Ms. Pelletier also became Private Evofem’s CEO. Concurrent with the forming of the WCGI Alliance, Private Evofem and WCGI entered into (i) a service agreement to which the companies shared resources and employees and (ii) a three -year grant agreement under which the Private Evofem provided funding of $4.0 million per year to WCGI. From 2011 to 2017, Ms. Pelletier served as a director of the board of WCGT, a WCGI subsidiary. As described in Note 6 — Commitments and Contingencies , (i) effective in February 2015, Private Evofem and WCGT entered into a sublease for office space, which was terminated and reassigned to WCG Cares effective April 1, 2018, and (ii) in October 2015, (a) Private Evofem, through its wholly-owned subsidiaries, entered into two sublicense agreements whereby Private Evofem was responsible for paying $5.0 million in annual sublicense fees, net of amounts paid under the grant agreement during 2015, to WCGCIC, also a WCGI affiliate, and (b) the service and grant agreements were canceled. Sublicense fees are included in R&D expenses in the consolidated statements of operations. In early 2015, Private Evofem became the corporate sponsor of WCGI’s “Then Who Will” educational campaign, which ended in late 2017. During the year ended December 31, 2017 , corporate support payments to vendors performing services for the “Then Who Will” campaign on behalf of WCGI totaled approximately $0.3 million , which were included in general and administrative expenses in the consolidated statements of operations. There were no such payments during the year ended December 31, 2018. Effective January 2016, Private Evofem and WCGI entered into a shared-services agreement (SSA), which replaced the prior service agreement. Under the terms of the SSA, Private Evofem and WCGI cross charge the other company’s services provided by each entity on behalf of the other. The SSA also allows for netting of due to and due from shared-services fees. Through December 31, 2016, Ms. Pelletier was being paid directly by each WCGI and Private Evofem. As of January 1, 2017, Ms. Pelletier was no longer paid directly by WCGI and was subject to Private Evofem’s SSA. Services provided under the SSA on behalf of WCGI totaled approximately $0.1 million and $0.8 million for the years ended December 31, 2018 and 2017 , respectively. As of December 31, 2018 and December 31, 2017 , net shared-services due to the Company was minimal for both periods. The following table summarizes receivables, payables, payments and expenses related to the Company’s transactions with WCGI related entities as of and for the years ended December 31, 2018 and 2017, respectively (in thousands): 2018 2017 Receivables $ 3 $ 17 Payables $ 1,292 $ 2,077 Payments $ 883 $ 1,026 Expenses $ 98 $ 89 Transactions with WCG Cares In 2013, WCG Cares, a 501(c)(3) nonprofit organization was incorporated under the laws of the State of California. Its primary purpose is to directly engage in and/or fund the development and implementation of programs that promote reproductive health, education, research and increased access to high-quality, innovative and affordable reproductive healthcare and healthcare products around the world. Ms. Pelletier served as the CEO and President of WCG Cares from 2013 to November 2017. She became a director of the board in November 2017 and served as chair of the board of directors from November 2017 to May 2018. Additionally, Mr. Justin J. File served as WCG Cares' Chief Financial Officer from November 2017 to May 2018. Dr. Kelly Culwell continues to serve as WCG Cares' Chief Medical Officer since November 2017, and also became a director of the board in January 2019 with a term of 3 years until December 31, 2021. See shared-services agreement discussion below. In August 2017, Private Evofem agreed to provide WCG Cares with $0.1 million in funding, which was paid to WCG Cares in October 2017, to support WCG Cares’ Women Deliver Young Leaders program. The Company also agreed to be a corporate sponsor of WCG Cares’ U.S. education campaign, the Tryst Network, which officially launched in February 2018. The Company paid WCG Cares a one-time payment of $0.3 million in March 2018 in connection with this corporate sponsorship of the Tryst Network. During the second quarter of 2018, the Company ceased being the corporate sponsor of the Tryst Network. As of December 31, 2018 and 2017, accrued Tryst-related costs totaled zero and $0.2 million , respectively. In March 2018, the Company and WCG Cares entered into a shared-services agreement (the Cares Shared-Services Agreement). Under the terms of the Cares Shared-Services Agreement, the Company and WCG Cares cross charge services provided by each entity (or its subsidiaries) on behalf of the other. The Cares Shared Services Agreement also allows for netting of due to and due from shared-services fees. As of December 31, 2018 , net shared-services due to the Company was minimal. The following table summarizes receivables, payables, payments and expenses related to the Company’s transactions with WCG Cares as of and for the years ended December 31, 2018 and 2017, respectively (in thousands): 2018 2017 Receivables $ 7 $ — Payables $ — $ 175 Payments $ 302 $ — Expenses $ 127 $ 175 Transactions with Women Deliver Women Deliver is a tax-exempt charitable organization under Section 501(c)(3) of the Internal Revenue Code. Its mission is to drive progress for gender equality, particularly in maternal, sexual, and reproductive health and rights globally through advocacy and Women Deliver programs. Ms. Pelletier became a director of the board in January 2013 and served as chair of the board of directors from May 2017 to July 2018. In July 2018, the Company and Women Deliver entered into a Corporate Sponsorship Agreement, under which the Company desired to become a corporate sponsor of the Women Deliver 2019 Conference and to provide financial support for Women Deliver programs. The Company agreed to pay $0.2 million to Women Deliver no later than January 31, 2019. As of December 31, 2018, this amount has not been paid. In February 2019, the Company received a letter from Women Deliver, under which both parties mutually agreed to release the Company's sponsorship on this outstanding payment. Variable Interest Entity Considerations Due to shared management and numerous agreements between the Company and WCGI, and the Company and WCG Cares, management reviewed its relationship with both WCGI and its subsidiaries and WCG Cares in accordance with the authoritative guidance for variable interest entities within ASC 810 - Consolidation . The Company concluded that due to WCGI’s and WCG Cares’ status as not-for-profit entities, the scope exception from qualifying as a variable interest entity was met and, therefore, the Company is not required to consolidate WCGI or WCG Cares.

Convertible Preferred Stock

Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock Immediately prior to the Merger, as described in Note 1- Description of Business and Basis of Presentation , each share of Private Evofem’s capital stock (other than Private Evofem’s Series D), including its Series A convertible preferred stock, Series B convertible preferred stock, Series C-1 convertible preferred stock and Series C convertible preferred stock was converted to the Company's common stock on a one-for-one basis effecting the Exchange Ratio and the Reverse Stock Split for an aggregate of 1,027,079 shares. In addition, each share of Private Evofem’s Series D was converted into approximately 85,987 shares of the Company's common stock for an aggregate of 6,878,989 shares. As of December 31, 2018 , no shares of convertible preferred stock were issued and outstanding. Dividends on the Series D were payable (i) upon conversion, (ii) redemption or (iii) liquidation. As such, although the Company’s board of directors had not declared dividends, the Company accrues dividends on the Series D. Upon closing of the Merger, the Company paid cash dividends of $0.2 million for the accrued dividends only for the period of January 6, 2018 to the Closing Date and the accrued and unpaid dividends of $5.2 million as of December 31, 2017 were reclassified to additional paid-in capital upon conversion of 80 shares of Series D into common stock. The designated, issued and outstanding shares of convertible preferred stock, by series, as of December 31, 2017 were as follows (aggregate liquidation amount and proceeds, net of issuance costs, in thousands): Shares Original Shares Common Aggregate Proceeds, Series A 12,768,492 $ 1.9579445 12,618,279 12,618,279 $ 24,706 $ 23,848 Series B 31,034,696 $ 3.2222 13,801,318 13,801,318 44,471 43,616 Series C-1 8,660,572 $ 3.97 8,558,686 8,558,686 33,978 34,382 Series C 5,037,784 $ 3.97 5,037,784 5,037,784 20,000 19,469 Series D (2)(3) 80 $ 500,000 80 85,160 39,739 Total 57,501,624 40,016,147 $ 208,315 $ 161,054 _______________________ (1) The Series D shares were convertible into shares in the next equity financing (either preferred or common) at a 50% discount to the fair value price per share of the shares to be issued in the next financing, therefore, the Series D common stock equivalents and the totals for common stock equivalents have been left blank. (2) Aggregate liquidation amount included accrued and unpaid dividends of $5.2 million as of December 31, 2017 . (3) Proceeds, net of issuance costs, included $35.0 million in cash and $5.0 million from the conversion of the Amended Cosmederm Note (see more discussions below) less issuance costs of approximately $0.3 million . This line excluded the Series D 2X liquidation preference net issuance price of $18.2 million , the loss on the issuance of Series D of $35.2 million , loss on extinguishment of related-party note payable of $6.7 million and accrued Series D dividends of $5.2 million . Private Evofem and Cosmederm entered a promissory note during 2015, which was amended in July 2016 in conjunction with the Private Evofem’s Series D financing (the Amended Cosmederm Note). Cosmederm assigned the Amended Cosmederm Note with the then outstanding principal balance of $10.0 million to WIM. As a condition to closing the Private Evofem’s Series D, WIM immediately converted $5.0 million of the Amended Cosmederm Note into 10 shares of the Private Evofem’s Series D and canceled the remaining $5.0 million . Series D In July 2016, Private Evofem entered into a Series D purchase agreement with WIM, which was subsequently amended in July 2017 to increase the number of authorized preferred stock for issuance (as amended, the Series D SPA). The Series D SPA authorized the issuance and sale of an aggregate of 80 shares of Series D, which was sold at an issuance price per share of $500,000 . WIM also received the right to receive warrant shares to be determined in the next equity financing (Warrant Rights). See Warrant Rights discussion below. Warrant Rights The Warrant Rights issued in connection with the issuance of Series D in 2016 and 2017 were convertible into warrants to purchase up to that number of equity securities to be issued in the next equity financing of Private Evofem equal to (i) seventy-five percent (75.0)% of the purchase price paid for the Series D (or $30.0 million ), divided by (ii) the per share price of the equity securities issued to the new investors in such next equity financing. The exercise price of the warrants will equal the per share price of the equity securities to be issued in the next equity financing and the warrants were to expire seven years from the closing of such next equity financing. The Warrant Rights were inseparable from the Series D. As of December 31, 2017, Private Evofem had not completed a next equity financing and, therefore, the Warrant Rights remained outstanding. Additionally, Private Evofem determined that since the exercise price of the warrants to be received by WIM was equal to the fair value of the shares for which the warrant would have become exercisable at issuance, there was de minimis value associated with the Warrant Rights and, therefore, Private Evofem did not record a warrant liability for the Warrant Rights as of December 31, 2017. Upon completion of the Merger, Private Evofem’s Series D Warrant Rights were assumed by the Company and exchanged for an aggregate of three shares of the Company's common stock and the WIM Warrants to purchase up to 2,000,000 shares of the Company's common stock. The shares of common stock issued in connection with the WIM Warrants may not be transferred separately from the WIM Warrants. The WIM Warrants will become exercisable on January 17, 2019 and shall remain exercisable until the earlier of January 18, 2022 or immediately prior to the completion of an acceleration event, as defined therein, and have an exercise price of $8.35 per share. The Company determined that the WIM Warrants are free standing financial instruments and classified as equity in accordance with ASC 480— Distinguish Liabilities from Equity. To determine the fair value of the WIM Warrants, the Company utilized the BSM option-pricing model, where the warrants exercise price was determined based on a Monte Carlo simulation. The valuations resulted in a concluded fair value of the WIM Warrants of $14.1 million as of January 18, 2018, which was recorded as additional paid-in capital in the consolidated balance sheet.

Public Offering

Public Offering	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Public Offering	Public Offering On May 24, 2018, the Company completed an underwritten public offering (the Offering), whereby the Company issued 7,436,171 shares of common stock at a public offering price of $4.69 per share and pre-funded warrants to purchase 1,063,829 shares of common stock at a public offering price of $4.68 per warrant and an exercise price of $0.01 per share. Each share of common stock and each pre-funded warrant was issued together with a common warrant to purchase one-fifth of a share of the Company's common stock at a public offering price of $0.01 per warrant and an exercise price of $7.50 per share. An aggregate of 8,500,000 common warrants were issued in connection with the Offering and are exercisable to purchase an aggregate of 1,700,000 shares of common stock. The common warrants issued to the three funds affiliated with WIM that participated in the Offering were issued as a unit with one share of common stock totaling three unit shares in the aggregate (the Unit Shares). Except with respect to the Unit Shares, the shares of common stock, pre-funded warrants and common warrants are separately transferable. The Company determined that the pre-funded warrants and common warrants are free standing financial instruments and equity classified in accordance with ASC 480- Distinguish Liabilities from Equity . The Company received proceeds from the Offering of approximately $37.5 million , net of underwriting discounts and commissions, but before deducting the estimated offering costs of $1.5 million . The estimated offering costs were recorded as contra additional-paid in capital in the consolidated balance sheet. The common stock and warrants issued in the Offering were registered pursuant to a registration statement on Form S-1 filed with the SEC on May 16, 2018 and declared effective on May 21, 2018. On June 26, 2018, the Company issued an additional 912 common warrants to purchase approximately 182 shares of common stock upon an underwriter's exercise of its overallotment option. The offering price and exercise price were the same as the common warrants issued on May 24, 2018. The net proceeds received from this issuance were immaterial. Stockholders' Deficit Warrants As of December 31, 2018 , warrants to purchase approximately 4,775,886 shares of the Company's common stock remain outstanding at a weighted average exercise price of $6.23 per share. These warrants include: • WIM Warrants to purchase up to 2,000,000 shares of common stock as described in Note 8- Convertible Preferred Stock , which became exercisable on January 17, 2019 and shall remain exercisable for three years unless there is a completion of an acceleration event as defined by the WIM Warrants agreements; • Warrants to purchase 11,875 shares of common stock that were issued prior to the Merger, which were exercisable as of December 31, 2018 and shall remain exercisable until 2020, 2022 and 2024; • Pre-funded warrants to purchase 1,063,829 shares of common stock issued in the Offering as described in Note 9- Public Offering , which were exercisable on May 24, 2018 and shall remain exercisable until shares are exercised; • Common warrants to purchase 1,700,000 shares of common stock issued in the Offering, which were exercisable on May 24, 2018 and shall remain exercisable for seven years; and • Common warrants to purchase approximately 182 shares of common stock upon exercise of the underwriter's overallotment option, which were exercisable on June 26, 2018 and shall remain exercisable for seven years. In February 2019, the Company issued an aggregate 2,376,062 shares of common stock upon exercise of WIM Warrants and common warrants issued in the Offering at a reduced exercise price of 2.64 per share. The Company received gross proceeds of approximately $6.3 million from these exercises. In addition, the Company issued new warrants to purchase 1,188,029 shares of common stock to investors who exercised warrants as aforementioned. See Note 15 - Subsequent Events for details. Common Stock Effective January 17, 2018 and in connection with the Merger, the Company amended and restated its certificate of incorporation, under which the Company is currently authorized to issue up to 300,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share. On January 17, 2018, immediately prior to the closing of the Merger, Private Evofem issued the Invesco Warrants for the purchase up to an aggregate of 3,980,437 shares of common stock, which were immediately net exercised on a cashless basis for 3,968,473 shares of the Company's common stock, effecting the Exchange Ratio and the Reverse Stock Split. The Company determined that the Invesco Warrants are free standing financial instruments and equity classified in accordance with ASC 480— Distinguish Liabilities from Equity. The Company had an external valuation completed as of January 17, 2018 with a concluded fair value of $47.9 million using the BSM option-pricing model, which was recorded as a loss on the issuance of Invesco Warrants within other income (expense) in the consolidated statement of operations, with corresponding entries to common stock par value for the shares issued and additional paid-in capital in the consolidated balance sheet. See Note 3- Merger and Related Transactions for more descriptions of the transactions completed in connection with the Merger. On May 24, 2018, the Company issued 7,436,171 shares of common stock upon closing of the Offering as described in Note 9- Public Offering . During the year ended December 31, 2018, the Company issued a total of 622,737 shares of common stock upon vesting of the RSAs and RSUs, net of shares repurchased for income tax withheld. At the Market Program On December 1, 2015, the Company entered into a Controlled Equity Offering Sales Agreement (Sales Agreement) with Cantor Fitzgerald & Co. (Cantor Fitzgerald) as a sales agent, pursuant to which the Company may offer and sell from time to time, through Cantor Fitzgerald, shares of the Company's common stock, par value $0.0001 per share, having an aggregate offering price of up to $20.0 million. The minimum share price for this Controlled Equity Offering is selected at the discretion of the Company’s board of directors. This at the market program expired in early December 2018 and no shares of common stock have been sold pursuant to this Sales Agreement during 2018. Common Stock Reserved for Future Issuance Common stock reserved for future issuance is as follows in common equivalent shares as of December 31, 2018 : Common stock issuable upon the exercise of stock options outstanding 5,767,627 Common stock issuable upon the exercise of common stock warrants 4,775,886 Common stock available for future issuance under the 2014 ESPP 118,825 Common stock available for future issuance under the Amended and Restated 2014 Plan 74,094 Common stock available for future issuance under the Inducement Plan 156,000 Total common stock reserved for future issuance 10,892,432

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Stockholders' Deficit	Public Offering On May 24, 2018, the Company completed an underwritten public offering (the Offering), whereby the Company issued 7,436,171 shares of common stock at a public offering price of $4.69 per share and pre-funded warrants to purchase 1,063,829 shares of common stock at a public offering price of $4.68 per warrant and an exercise price of $0.01 per share. Each share of common stock and each pre-funded warrant was issued together with a common warrant to purchase one-fifth of a share of the Company's common stock at a public offering price of $0.01 per warrant and an exercise price of $7.50 per share. An aggregate of 8,500,000 common warrants were issued in connection with the Offering and are exercisable to purchase an aggregate of 1,700,000 shares of common stock. The common warrants issued to the three funds affiliated with WIM that participated in the Offering were issued as a unit with one share of common stock totaling three unit shares in the aggregate (the Unit Shares). Except with respect to the Unit Shares, the shares of common stock, pre-funded warrants and common warrants are separately transferable. The Company determined that the pre-funded warrants and common warrants are free standing financial instruments and equity classified in accordance with ASC 480- Distinguish Liabilities from Equity . The Company received proceeds from the Offering of approximately $37.5 million , net of underwriting discounts and commissions, but before deducting the estimated offering costs of $1.5 million . The estimated offering costs were recorded as contra additional-paid in capital in the consolidated balance sheet. The common stock and warrants issued in the Offering were registered pursuant to a registration statement on Form S-1 filed with the SEC on May 16, 2018 and declared effective on May 21, 2018. On June 26, 2018, the Company issued an additional 912 common warrants to purchase approximately 182 shares of common stock upon an underwriter's exercise of its overallotment option. The offering price and exercise price were the same as the common warrants issued on May 24, 2018. The net proceeds received from this issuance were immaterial. Stockholders' Deficit Warrants As of December 31, 2018 , warrants to purchase approximately 4,775,886 shares of the Company's common stock remain outstanding at a weighted average exercise price of $6.23 per share. These warrants include: • WIM Warrants to purchase up to 2,000,000 shares of common stock as described in Note 8- Convertible Preferred Stock , which became exercisable on January 17, 2019 and shall remain exercisable for three years unless there is a completion of an acceleration event as defined by the WIM Warrants agreements; • Warrants to purchase 11,875 shares of common stock that were issued prior to the Merger, which were exercisable as of December 31, 2018 and shall remain exercisable until 2020, 2022 and 2024; • Pre-funded warrants to purchase 1,063,829 shares of common stock issued in the Offering as described in Note 9- Public Offering , which were exercisable on May 24, 2018 and shall remain exercisable until shares are exercised; • Common warrants to purchase 1,700,000 shares of common stock issued in the Offering, which were exercisable on May 24, 2018 and shall remain exercisable for seven years; and • Common warrants to purchase approximately 182 shares of common stock upon exercise of the underwriter's overallotment option, which were exercisable on June 26, 2018 and shall remain exercisable for seven years. In February 2019, the Company issued an aggregate 2,376,062 shares of common stock upon exercise of WIM Warrants and common warrants issued in the Offering at a reduced exercise price of 2.64 per share. The Company received gross proceeds of approximately $6.3 million from these exercises. In addition, the Company issued new warrants to purchase 1,188,029 shares of common stock to investors who exercised warrants as aforementioned. See Note 15 - Subsequent Events for details. Common Stock Effective January 17, 2018 and in connection with the Merger, the Company amended and restated its certificate of incorporation, under which the Company is currently authorized to issue up to 300,000,000 shares of common stock, $0.0001 par value per share, and 5,000,000 shares of preferred stock, $0.0001 par value per share. On January 17, 2018, immediately prior to the closing of the Merger, Private Evofem issued the Invesco Warrants for the purchase up to an aggregate of 3,980,437 shares of common stock, which were immediately net exercised on a cashless basis for 3,968,473 shares of the Company's common stock, effecting the Exchange Ratio and the Reverse Stock Split. The Company determined that the Invesco Warrants are free standing financial instruments and equity classified in accordance with ASC 480— Distinguish Liabilities from Equity. The Company had an external valuation completed as of January 17, 2018 with a concluded fair value of $47.9 million using the BSM option-pricing model, which was recorded as a loss on the issuance of Invesco Warrants within other income (expense) in the consolidated statement of operations, with corresponding entries to common stock par value for the shares issued and additional paid-in capital in the consolidated balance sheet. See Note 3- Merger and Related Transactions for more descriptions of the transactions completed in connection with the Merger. On May 24, 2018, the Company issued 7,436,171 shares of common stock upon closing of the Offering as described in Note 9- Public Offering . During the year ended December 31, 2018, the Company issued a total of 622,737 shares of common stock upon vesting of the RSAs and RSUs, net of shares repurchased for income tax withheld. At the Market Program On December 1, 2015, the Company entered into a Controlled Equity Offering Sales Agreement (Sales Agreement) with Cantor Fitzgerald & Co. (Cantor Fitzgerald) as a sales agent, pursuant to which the Company may offer and sell from time to time, through Cantor Fitzgerald, shares of the Company's common stock, par value $0.0001 per share, having an aggregate offering price of up to $20.0 million. The minimum share price for this Controlled Equity Offering is selected at the discretion of the Company’s board of directors. This at the market program expired in early December 2018 and no shares of common stock have been sold pursuant to this Sales Agreement during 2018. Common Stock Reserved for Future Issuance Common stock reserved for future issuance is as follows in common equivalent shares as of December 31, 2018 : Common stock issuable upon the exercise of stock options outstanding 5,767,627 Common stock issuable upon the exercise of common stock warrants 4,775,886 Common stock available for future issuance under the 2014 ESPP 118,825 Common stock available for future issuance under the Amended and Restated 2014 Plan 74,094 Common stock available for future issuance under the Inducement Plan 156,000 Total common stock reserved for future issuance 10,892,432

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation Equity Incentive Plans In September 2012, Private Evofem adopted the 2012 Equity Incentive Plan (the 2012 Plan) that provides for the issuance of RSAs, RSUs, or non-qualified and incentive common stock options to its employees, non-employee directors and consultants, from its authorized shares. In general, the options expire ten years from the date of grant and generally vest either (i) over a four -year period, with 25% exercisable at the end of one year from the employee’s hire date and the balance vesting ratably thereafter or (ii) over a three -year period, with 25% exercisable at the grant date and the balance vesting ratably thereafter. Upon completion of the Merger, Private Evofem's 2012 Plan was assumed by the Company and awards outstanding under the 2012 Plan became awards for the Company's common stock. Effective as of the Merger, no further awards may be issued under the 2012 Plan. On September 15, 2014, Neothetics' board of directors adopted, and stockholders approved, the 2014 Equity Incentive Plan (the 2014 Plan). On March 9, 2018, the Company's board of directors approved, subject to stockholder approval, and recommended its stockholders approve at the annual meeting held on May 8, 2018, the amendment and restatement of the 2014 Plan (the Amended and Restated 2014 Plan), that, among other things, would increase the number of authorized shares under the 2014 Plan from 749,305 to an aggregate of 5,300,000 shares. Such stockholder approval was obtained on May 8, 2018. On November 28, 2018, the Company's board of directors approved, subject to stockholder approval, and recommended its stockholders approve at the 2019 annual meeting, an additional 2,500,000 authorized shares reserved for issuance under the Amended and Restated 2014 Plan to an aggregate of 7,800,000 shares. As of December 31, 2018 , there were 74,094 shares available to grant under the Amended and Restated 2014 Plan, which did not include the additional share increase aforementioned and 1,013,375 Contingent Options granted. On July 24, 2018, upon the recommendation by the Compensation Committee, the board of directors adopted the Evofem Biosciences, Inc. 2018 Inducement Equity Incentive Plan (the Inducement Plan), pursuant to which the Company reserved 250,000 shares for the issuance of equity awards under the Inducement Plan. The only persons eligible to receive awards under the Inducement Plan are individuals who satisfy the standards for inducement grant recipients under Nasdaq Marketplace Rule 5635(c)(4), generally, a person not previously an employee or director of the Company, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with the Company. As of December 31, 2018 , there were 156,000 shares available to grant under the Inducement Plan. The following table summarizes stock-based compensation expense related to stock options, RSAs and RSUs granted to employees and nonemployees included in the consolidated statements of operations as follows (in thousands): Years Ended December 31, 2018 2017 Research and development $ 3,193 $ 184 General and administrative 14,649 677 Total $ 17,842 $ 861 Stock Options The following table summarizes share option activity for the year ended December 31, 2018: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value (1) (in thousands) Outstanding as of December 31, 2017 160,248 $ 56.66 7.80 — Granted (2) 5,570,675 $ 6.33 Assumed from Neothetics (3) 246,810 $ 14.31 Exercised (6,173 ) $ 6.78 Forfeited (203,933 ) $ 11.71 Outstanding as of December 31, 2018 5,767,627 $ 7.00 9.01 $ 3,211 Options exercisable as of December 31, 2018 3,034,283 $ 9.58 8.59 $ 342 Options vested and expected to vest as of December 31, 2018 5,767,627 $ 7.00 9.01 $ 3,211 _______________________ (1) As of December 31, 2017, the fair value of the Company’s common shares as determined by its board of directors was $0.31 per share. (2) The number of shares granted included 1,013,375 shares of Contingent Options granted on November 28, 2018 out of the share reserve increase approved by the board of directors under the Amended and Restated 2014 Plan, and were subject to the Company obtaining the requisite stockholder approval at the 2019 annual meeting. (3) The number of shares assumed from Neothetics represents outstanding stock options as of January 17, 2018 owned by Neothetics' employees in conjunction with the Merger. The following table summarizes certain information regarding stock options for the years ended December 31, 2018 and 2017 (in thousands, except per share data): 2018 2017 Weighted average grant date fair value per share of options granted during the period $ 3.99 $ 32.34 Fair value per share of options vested during the period $ 4.58 $ 35.52 Cash received from options exercised during the period $ 42 $ — Intrinsic value of options exercised during the period $ 12 $ — The Company recognized $14.7 million and $0.9 million stock-based compensation expense related to stock options for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018 , unrecognized stock-based compensation expense for employees and non-employee stock options was approximately $5.1 million , which the Company expects to recognize over a weighted-average remaining period of 2.2 years, assuming all unvested options become fully vested. Summary of Assumptions The fair value of stock-based compensation for stock options granted to employees and nonemployees was estimated on the date of grant using the BSM option-pricing model based on the following weighted-average assumptions for options granted for the periods indicated. Years Ended December 31, 2018 2017 Expected volatility 87.0 % 90.9 % Risk-free interest rate 2.9 % 2.2 % Expected dividend yield — % — % Expected term (years) 5.5 5.9 Expected volatility. The expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. Risk-free interest rate. The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the stock option grants. Expected dividend yield. The expected dividend yield assumption is based on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends. Expected term. The expected term represents the period options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected term assumption using the practical expedient as provided for under ASC 718 — Compensation — Stock Compensation , which is the midpoint between the requisite service period and the contractual term of the option. Restricted Stock Awards and Units The following table summarizes RSAs and RSUs activity for the year ended December 31, 2018: Shares (RSAs) Weighted Average Fair Value per Share Shares (RSUs) Weighted Average Fair Value per Share Unvested as of December 31, 2017 122,149 $ 48.72 2,566 $ 48.72 Granted 1,230,399 $ 2.46 75,000 $ 2.46 Canceled (122,149 ) $ 48.72 (2,566 ) $ 48.72 Released (1,185,399 ) $ 2.72 (75,000 ) $ 2.46 Unvested as of December 31, 2018 45,000 $ 2.46 — $ — In September 2016, under the 2012 Equity Incentive Plan, Private Evofem issued an aggregate of 122,149 shares of restricted stock to members of management (the Management RSAs) with vesting terms subject to the completion of an initial public offering (IPO) by Private Evofem. In October 2016, as previously described in Note 7 — Related-party Transactions , Private Evofem issued a restricted stock unit for the right to 2,566 shares of common stock to the chairman of the Company’s board of directors (the Chairman RSUs). Upon closing of the Merger, as more fully described in Note 1 – Description of Business and Basis of Presentation , the members of management and the chairman of the board of directors agreed to cancel their RSAs and RSUs. As a result, all 122,149 shares of unvested Management RSAs and 2,566 shares of unvested Chairman RSUs were canceled in January 2018, and there was no unrecognized stock-based compensation expense related to the canceled Management RSAs and Chairman RSUs. On July 2, 2018, under the Amended and Restated 2014 Plan, the Company issued an aggregate of 1,230,399 shares of RSAs to its executive management team, of which 10,000 shares will vest based on certain performance conditions, 35,000 shares vested on October 16, 2018 and will vest on October 16, 2019, respectively, upon completion of the grantee's services for the Company, and the remaining 1,150,399 shares immediately vested on the grant date. The non-performance-based RSAs were valued at the fair value on the grant date and the associated expenses were fully recognized on the grant date. For the performance-based RSAs, (i) the fair value of the award was determined on the grant date, (ii) the Company assessed the probability of the individual milestone under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met. On July 2, 2018, under the Amended and Restated 2014 Plan, the Company also issued 75,000 shares of RSUs to the chairman of the Company’s board of directors in consideration for certain consulting services provided to the Company in connection with the 2016 Consulting Agreement. The RSUs were fully vested on the grant date. The Company recognized $3.2 million and zero stock-based compensation expense related to RSAs and RSUs for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, unrecognized stock-based compensation expense related to the unvested RSAs was approximately $0.1 million , which the Company expects to recognize over a weighted-average remaining period of 0.7 year. Employee Stock Purchase Plan In November 2014, Neothetics adopted the 2014 Employee Stock Purchase Plan (the ESPP), which enables eligible employees to purchase shares of its common stock using their after-tax payroll deductions of up to 15% of their eligible compensation, subject to certain restrictions. The ESPP initially authorized the issuance of 28,333 shares of common stock pursuant to purchase rights granted to employees. The number of shares of common stock reserved for issuance automatically increased on January 1, 2015 and will continue to increase on each January 1 thereafter through January 1, 2024, by the smaller of (a) 1.0% of the total issued and outstanding shares on the preceding December 31, and (b) a number of shares determined by the board of directors of Neothetics. The ESPP is intended to qualify as an employee stock purchase plan within the meaning of Section 423 of the Internal Revenue Code of 1986, as amended (the IRC). The fair value of shares issued to employees under the ESPP is estimated using a BSM option-pricing model, which requires the use of subjective and complex assumptions, including (a) the expected stock price volatility, (b) the calculation of the expected term of the award, (c) the risk-free interest rate and (d) the expected dividend yield. Following completion of the Merger, there was no enrollment in the ESPP. During the years ended December 31, 2018 and 2017, there were no shares of common stock purchased under the ESPP.

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2018
Retirement Benefits [Abstract]
Employee Benefits	Employee Benefits The Company has a defined contribution 401(k) plan for all qualifying employees. Employees are eligible to participate in the plan beginning on the first day of the month following their three-month anniversary of employment. Under the terms of the plan, employees may make voluntary contributions as a percent of their compensation. The Company makes a safe-harbor contribution of three percent ( 3.0 )% of each employee’s gross earnings, subject to Internal Revenue Service limitations. In the years ended December 31, 2018 and 2017 , the Company made safe-harbor contributions of approximately $0.1 million for both periods.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company is subject to taxation in the U.S., United Kingdom and various states jurisdictions. Tax years since Neothetics and Private Evofem's inception of 2007 and 2009, respectively, remain open to examination by the major taxing jurisdictions to which they are subject to. The Company’s consolidated pretax loss for the years ended December 31, 2018 and 2017 were generated by domestic and foreign operations as follows (in thousands): 2018 2017 United States $ (125,670 ) $ (105,222 ) Foreign (40 ) (80 ) Total $ (125,710 ) $ (105,302 ) Income tax provision for the years ended December 31, 2018 and 2017 consisted of the following (in thousands): 2018 2017 United States $ — $ — State (2 ) (3 ) Foreign — — Total current tax provision (2 ) (3 ) Total deferred tax provision — — Total $ (2 ) $ (3 ) The reconciliation between the Company’s effective tax rate on loss before income tax and the statutory tax rate for the years ended December 31, 2018 and 2017 was as follows: 2018 2017 Statutory rate 21.00 % 34.00 % State income tax, net of federal benefit 0.21 % (0.34 )% Nondeductible expenses (0.56 )% (0.46 )% Equity-based expenses (1.03 )% (2.93 )% Loss on issuance of warrants (8.01 )% — % Change in fair value of Series D 2X liquidation preference (0.02 )% (19.75 )% Return to provision 0.03 % 0.19 % Tax credits 1.60 % 1.35 % Uncertain tax positions (0.57 )% (0.34 )% Foreign rate differential (0.01 )% (0.03 )% Rate adjustment 0.19 % (22.26 )% Change in valuation allowance (12.83 )% 10.57 % Effective tax rate — % — % Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s net deferred tax assets arising from its taxable subsidiaries consisted of the following components as of December 31, 2018 and 2017 (in thousands): 2018 2017 Deferred tax assets: Net loss carryforwards $ 53,933 $ 42,281 Fixed assets and intangibles 672 89 Research and development credits 5,948 3,808 Stock-based compensation 3,905 1,394 Other 747 846 Total deferred tax assets 65,205 48,418 Less: valuation allowance (65,205 ) (48,418 ) Net deferred tax assets $ — $ — In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all the deferred tax assets will be realized. Generally, the ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based on historical performance and future expectations, management has determined a valuation allowance is needed in respect to its ending deferred tax assets. As of December 31, 2018 , the Company had net operating loss (NOL) carryforwards for federal income tax purposes of approximately $227.9 million , which will begin to expire in 2029 if not utilized. As of December 31, 2018 , the Company had NOL carryforwards in various states of approximately $106.7 million . The state carryforwards have varying expiration dates beginning in 2029. The Company has foreign NOLs of $0.6 million that do not expire. As of December 31, 2018, the Company has federal and state R&D tax credit carryforwards of approximately $6.8 million and $1.5 million , respectively. As of December 31, 2017, the Company has federal and state R&D tax credit carryforwards of approximately $4.1 million and $1.2 million , respectively. The federal R&D tax credits begin to expire in 2031, unless utilized, and the state credits do not expire. The following table summarized the activity related to the Company’s gross unrecognized tax benefits as of December 31, 2018 and 2017 (in thousands): 2018 2017 Balance at the beginning of the year $ 1,335 $ 970 Adjustments related to prior year tax positions 162 (5 ) Increases related to current year tax positions 564 370 Decreases due to statute of limitation expiration — — Balance at end of year $ 2,061 $ 1,335 The Company recognizes a tax benefit from an uncertain tax position when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits, and uncertain income tax positions must meet a more likely than not recognition threshold to be recognized. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line in the consolidated statements of operations. There were no accrued interest and penalties associated with unrecognized tax benefits as of December 31, 2018 . The Company does not anticipate a significant change in its uncertain tax benefits over the next 12 months. Management believes it is more likely than not that all significant tax positions taken to date would be sustained by the relevant taxing authorities. Furthermore, the Company has not recognized any tax benefits to date because the Company has established a full valuation allowance for its deferred tax assets due to uncertainties as to their ultimate realization. Pursuant to IRC Sections 382 and 383, annual use of the Company’s NOLs and R&D credit carryforwards may be limited in the event a cumulative change in ownership of more than 50.0% occurs within a three-year period. The Company has not completed an IRC Section 382/383 analysis regarding the limitation of NOLs and R&D credit carryforwards; due to the complexity and cost associated with such a study and the fact that there may be additional such ownership changes in the future. The Company does not expect this analysis to be completed within the next 12 months and as a result, the Company does not expect the unrecognized tax benefits will change within 12 months of this reporting date. Due to the existence of the valuation allowances, future changes in the Company’s unrecognized tax benefits will not impact the Company’s effective tax rate. If the Company has experienced an ownership change at any time since its’s formation, utilization of the NOLs or R&D tax credit carryforwards would be subject to an annual limitation under Section 382 of the IRC, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term tax-exempt rate and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs or R&D tax credit carryforwards before utilization. On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the Tax Act). The Tax Act makes broad and complex changes to the U.S. tax code, including but not limited to (i) reducing the U.S. federal tax rate from 35% to 21% as of January 1, 2018, (ii) requiring companies to pay a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries, (iii) generally eliminating the U.S. federal income tax on dividends from foreign subsidiaries, (iv) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations, (v) eliminating the corporate alternative minimum tax (AMT) and changing how existing AMT credits can be realized, (vi) creating the base erosion anti-abuse tax, a new minimum tax, (vii) creating a new limitation on deductible interest expense, and (viii) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017. As a result of the accounting implications of the Tax Act, the Company recorded a decrease related to its deferred tax assets of approximately $0.2 million and $18.4 million , with a corresponding net adjustment to the valuation allowance for the year ended December 31, 2018 and 2017, respectively.

Selected Quarterly Financial Da

Selected Quarterly Financial Data (unaudited)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (unaudited)	Selected Quarterly Financial Data (unaudited) The following table contains quarterly financial information for 2018 and 2017 . The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period. First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) Year Ended December 31, 2018 Total operating expense $ 20,986 $ 23,242 $ 18,433 $ 14,981 Other (income) expense 48,070 — (2 ) — Net loss (69,056 ) (23,244 ) (18,431 ) (14,981 ) Net loss attributable to common stockholders (69,122 ) (23,244 ) (18,431 ) (14,981 ) Net loss per share attributable to common stockholders, basic and diluted (4.62 ) (1.11 ) (0.71 ) (0.58 ) Year Ended December 31, 2017 Total operating expense $ 4,913 $ 6,358 $ 9,070 $ 15,346 Other expense 353 154 64,961 4,147 Net loss (5,269 ) (6,512 ) (74,031 ) (19,493 ) Net loss attributable to common stockholders (6,157 ) (7,409 ) (75,085 ) (20,671 ) Net loss per share attributable to common stockholders, basic and diluted (3.14 ) (3.78 ) (38.31 ) (10.55 )

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Subsequent events were evaluated through the filing date of this Annual Report, March 1, 2019. On February 5, 2019, the Company entered into letter agreements (Repricing Letter Agreements) with certain holders (Holders) of issued and outstanding warrants (Warrants) to purchase the Company's common stock. The Repricing Letter Agreements offered the Holders the opportunity to exercise their Warrants for cash at reduced exercise prices equal to 80% of the closing price of the Company’s stock reported by the Nasdaq Capital Market on the respective dates of the Repricing Letter Agreements. Upon execution of the Repricing Letter Agreements, Holders exercised their Warrants to purchase an aggregate 2,376,062 shares of common stock at an exercise price of $ 2.64 per share. The Company received gross proceeds of approximately $6.3 million from these exercises. In addition, under the Repricing Letter Agreements the Company issued warrants to purchase up to 1,188,029 shares of the Company's common stock (Reload Warrants) to Holders at an exercise price of $5.20 per share, which is equal to 160% multiplied by the closing price as reported by the Nasdaq Capital Market on the issue date of February 8, 2019 of the Reload Warrants. On February 25, 2019, the Compensation Committee, with the authorization of the Board of Directors, approved a total of 460,500 shares of performance-based RSAs to its executive management team and certain non-executive employees under the Amended and Restated 2014 Plan. The performance-based RSAs will vest in accordance with the Company's achievement of certain performance milestones in 2019.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation and Principles	Basis of Presentation and Principles of Consolidation Since Private Evofem was determined to be the accounting acquirer in connection with the Merger, it recorded Neothetics’ assets and liabilities at fair value as of the Closing Date. Therefore, for periods prior to the Merger, the consolidated financial statements were prepared on a stand-alone basis for Private Evofem and did not include the combined entities' financial position. Subsequent to the Merger, the consolidated financial statements as of and for the year ended December 31, 2018 from the Closing Date included Neothetics' assets and liabilities. The Company prepared the consolidated financial statements in accordance with accounting principles generally accepted in the U.S. (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC) related to annual reports on Form 10-K.
Consolidation	The Company’s financial statements are presented on a consolidated basis, which include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the notes thereto. S ignificant estimates affecting amounts reported or disclosed in the consolidated financial statements include, but not limited to, the measurement of the Series D 2X liquidation preference, assumptions used in estimating the fair value of warrants issued in connection with the Merger, the useful lives of property and equipment, the recoverability of long-lived assets, preclinical and clinical trial accruals, assumptions used in estimating the fair value of stock-based compensation expense and other contingencies. The Company’s assumptions regarding the measurement of the Series D 2X liquidation preference and stock-based compensation are more fully described in Note 5 — Fair Value of Financial Instruments and Note 11 — Stock-based Compensation, respectively. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker, who is the Chief Executive Offer (CEO) of the Company, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking and time deposit accounts are maintained in federally insured financial institutions in excess of federally insured limits. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets. The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents consists of readily available cash in checking and money market accounts. Restricted cash consists of cash held in monthly time deposit accounts, which are collateral for the Company’s credit cards and facility leases.
Property and Equipment	Property and Equipment Property and equipment generally consist of research equipment, computer equipment and software and office furniture, and are recorded at cost and depreciated over the estimated useful lives of the assets (generally three to five years ) using the straight-line method. Leasehold improvements are stated at cost and are amortized on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful lives of the assets. Repairs and maintenance costs are charged to expense as incurred and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheets and any resulting gain or loss is reflected in the consolidated statements of operations in the period realized.
Impairment of Long-Lived Assets	Impairment of Long-lived Assets The Company reviews property and equipment for impairment on an annual basis and whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss would be recognized when estimated future undiscounted cash flows relating to the asset or asset group are less than its carrying amount. An impairment loss is measured as the amount by which the carrying amount of an asset or asset group exceeds its fair value. While the Company’s current and historical operating losses and negative cash flows are possible indicators of impairment, management believes that future cash flows to be generated by these assets support the carrying value of its long-lived assets and, accordingly, did not recognize any impairment losses during the years ended December 31, 2018 and 2017 .
Clinical Trial Accruals	Clinical Trial Accruals As part of the process of preparing our financial statements, we are required to estimate expenses resulting from our obligations under contracts with vendors, clinical research organizations (CROs), consultants and under clinical site agreements relating to conducting our clinical trials. The financial terms of these contracts vary and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company's objective is to reflect the appropriate clinical trial expenses in our consolidated financial statements by recording those expenses in the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by patient progression and the timing of various aspects of the trial. Management determines accrual estimates through financial models and discussions with applicable personnel and outside service providers as to the progress of clinical trials. During a clinical trial, the Company adjusts the clinical expense recognition if actual results differ from its estimates. The Company makes estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. The Company’s clinical trial accruals are partially dependent upon accurate reporting by CROs and other third-party vendors. Although the Company does not expect its estimates to differ materially from actual amounts incurred, the Company’s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low for any period. For the years ended December 31, 2018 and 2017 there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials.
Fair Value	Fair Value of Series D and Series D 2X Liquidation Preference Prior to completion of the Merger, the Company valued its Series D redeemable convertible preferred stock (Series D) and Series D 2X liquidation preference in accordance with Accounting Standards Codification (ASC) No. 815 — Derivatives and Hedging , using a probability-weighted expected return model (PWERM), which is sensitive to changes in assumptions regarding the timing of additional financings, potential exit scenarios and revisions in our financial forecast. Changes in any one of the assumptions could have had a material impact on the estimated fair value of the Series D and Series D 2X liquidation preference. Management used the most reliably available information at each issuance of Series D to determine the fair value of the Series D and at each valuation date to determine the fair value of the Series D 2X liquidation preference. Due to the nature of the assumptions and the sensitive nature of the PWERM, management could not reliably provide sensitivity analysis around the impact of changes in assumptions utilized in the PWERM used to estimate the fair value of the Series D and Series D 2X liquidation preference. Fair Value of Financial Instruments The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, that are required to be recorded at fair value, the Company considers the principal or most advantageous market in which to transact and the market-based risk. The Company applies fair value accounting for all assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. The valuation of assets and liabilities are subject to fair value measurements using a three-tiered approach and fair value measurement is classified and disclosed by the Company in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, restricted cash, accounts payable, note payable, accrued expenses and accrued compensation approximate their fair values due to their short-term nature. As of December 31, 2018 and 2017 , based on the borrowing rate currently available to the Company for loans with similar terms, which is considered a Level 2 input, the Company believes the fair value of the Flex Note (as defined below) approximates its carrying value. Fair Value of Warrants The fair value of the WIM and Invesco Warrants (as defined below) issued in connection with the Merger were determined using the Black-Scholes-Merton (BSM) option-pricing model based on the applicable assumptions, which include the warrants exercise price, time to expiration, expected volatility of our peer group, risk-free interest rate and expected dividend.
Convertible Preferred Stock	Convertible Preferred Stock Prior to the Merger, the Company’s Series A, Series B, Series C-1, Series C convertible preferred stock and Series D were classified as temporary equity instead of stockholders’ deficit in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities, as the shares were conditionally redeemable at the holder’s option and upon certain change in control events that are outside the Company’s control, including liquidation, sale, or transfer of control of the Company. Upon completion of the Merger, the Company's Series A, Series B, Series C-1, Series C convertible preferred stock and Series D were converted into common stock.
Research and Development	Research and Development R&D expenses include the costs associated with the Company’s R&D activities, including, but not limited to, payroll and personnel-related expenses, stock-based compensation expense, materials, laboratory supplies, clinical studies and outside services. R&D costs are expensed as incurred, except when accounting for nonrefundable advance payments for goods or services not yet received. These payments, if any, are capitalized at the time of payment and expensed as the related goods are delivered or the services are performed.
Patent Expense	Patent Expenses The Company expenses all costs incurred relating to patent applications (including direct application fees, and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the consolidated statements of operations.
Stock-based Compensation	Stock-based Compensation Stock-based compensation expense for equity instruments issued to employees, nonemployee directors and consultants is measured based on estimating the fair value of each stock option on the date of grant using the BSM option-pricing model. Expensing The following table summarizes the Company’s stock-based awards expensing policies for employees and nonemployees: Employees and Nonemployee Consultants After Adopting ASU 2018-07 Nonemployee Consultants Prior to Adopting ASU 2018-07 Service only condition Straight-line based on the grant date fair value Re-value at each reporting date through the service commitment date Performance criterion is probable of being met: Service criterion is complete Recognize the grant date fair value of the award(s) once the performance criterion is considered probable of occurrence Re-value the award(s) once the performance criterion is considered probable of occurrence and recognize expense for the then fair value of the award(s) Service criterion is not complete Expense using an accelerated multiple-option approach (1) over the remaining requisite service period Same as for employees, except the award will be marked-to-market through the performance commitment date Performance criterion is not probable of being met and: Is not tied to the successful completion of an initial public offering of the Company’s common stock (IPO) No expense recognition is required until the performance criterion is considered probable at which point expense is recognized using an accelerated multiple-option approach Same as for employees, except the award will be marked-to-market through the performance commitment date Is tied to the successful completion of an IPO by the Company Upon closing of an IPO by the Company, recognize the grant date fair value of the award(s) Same as for employees, except expense is recognized based upon the fair value of the Company’s common stock sold in the IPO ________________ (1) The accelerated multiple-option approach results in compensation expense being recognized for each separately vesting tranche of the award as though the award was in substance multiple awards and, therefore, results in accelerated expense recognition during the earlier vesting periods. Determining Fair Value of Stock Options Prior to the Merger, the fair value of the shares of the Company’s common stock underlying its stock-based awards was estimated on each grant date by the Company’s board of directors. To determine the fair value of the common stock underlying option grants, the Company’s board of directors considered, among other things, valuations of the Company’s common stock prepared by an unrelated valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Given the absence of a public trading market for its common stock prior to completion of the Merger, the board of directors exercised reasonable judgment and considered a number of objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock, including the Company’s stage of development; progress of the Company’s R&D efforts; the Company’s operating and financial performance, including levels of available capital resources; the rights, preferences and privileges of the Company’s convertible preferred stock relative to those of its common stock; sales of the Company’s convertible preferred stock; the valuation of publicly traded companies in its industry, equity market conditions affecting comparable public companies and the lack of marketability of the Company’s common stock. The Company obtained valuations on at least an annual basis or when it determined that significant value generating or diminishing internal and/or external events had occurred which would significantly increase or decrease the fair value of the common stock underlying its stock-based awards. Post the Merger, the fair value of our common stock will be equal to the closing price of our stock. For purposes of re-measuring the Company’s consultant stock options, the Company utilized the concluded fair values for the Company’s common stock underlying the stock options as aforementioned prior to the Merger or the closing price at each reporting date post the Merger to recognize estimated consultant stock-based compensation expense using the BSM at each reporting date. Forfeitures The Company adopted ASU No. 2016-09 Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU No. 2016-09) in fiscal year 2016, under which the Company made a one-time policy election to record forfeitures when they occur. Performance-based Awards For performance-based restricted stock awards (RSAs) (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual milestone under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.
Income Taxes	Income Taxes The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position. The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.
Net Loss Per Share	Net Loss Per Share Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were the same for all periods presented.
Recently Adopted and Recently Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements The Company qualifies as an “emerging growth company” (EGC) pursuant to the provisions of the Jumpstart Our Business Startups (JOBS) Act from the fiscal year 2014 to 2018. Section 7(a)(2)(B) of the Securities Act of 1933, as amended, permits EGCs to defer compliance with new or revised accounting standards until non-issuers are required to comply with such standards. However, the Company elected not to take advantage of the extended transition period for implementation of new or revised financial accounting standards, and as a result, the Company will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU No. 2014-09), which amends the existing accounting standards for revenue recognition. ASU No. 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. The new standard as amended by ASU No. 2015-14 ( Revenue from Contracts with Customers (Topic 606): Deferral of The Effective Date) , ASU No. 2016-10 ( Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligation and Licensing), and ASU No. 2016-12 ( Revenue from Contracts with Customers (Topic 606): Narrow-scope Improvements and Practical Expedients) was effective for the Company beginning January 1, 2018. The Company adopted the new standard using the full retrospective approach, which did not have an impact on the Company’s financial position or results of operations as the Company is pre-revenue and does not anticipate generating any significant revenue prior to 2020. In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting (ASU No. 2017-09), which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. ASU No. 2017-09 was effective for the Company beginning January 1, 2018. The adoption of this new standard did not have a material impact on the Company’s financial position or results of operations. In June 2018, the FASB issued ASU No. 2018-07, Compensation- Stock Compensation (Topic 718 ) (ASU No. 2018-07), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees that are currently covered under Accounting Standards Codification (ASC) 505-50 , Equity-Based Payments to Non-employees. ASU No. 2018-07 will be effective for the Company beginning January 1, 2019 and early adoption is permitted. The Company adopted this new standard on September 30, 2018 using a modified retrospective transition method, under which the Company valued the equity awards to nonemployees as of September 30, 2018; any expense recorded for the awards in the future will be based on this value. There was no cumulative effect of the change on retained earnings. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842 ) (ASU No. 2016-02), which changes the presentation of assets and liabilities relating to leases. The core principle of ASU No. 2016-02 is that a lessee should recognize the assets and liabilities that arise from leases. The new standard as amended by ASU No. 2018-01 ( Leases (Topic 842 ): Land Easement Practical Expedient for Transition to Topic 842 ), ASU No. 2018-10 ( Codification Improvements to Topic 842, Leases ), and ASU No. 2018-11 ( Leases (Topic 842): Targeted Improvements ) (ASC No. 2018-11) was effective for the Company beginning January 1, 2019. This new standard is required to be adopted using a modified retrospective approach with certain available transitional practical expedients. The ASU No. 2018-11 issued in July 2018 allows for the adoption of the new standard to be applied at the adoption date as opposed to at the beginning of the earliest year presented. On January 1, 2019, the Company adopted this new standard under the provisions allowed under ASU 2018-11. Based on the Company's evaluation of impact on its financial statements, the Company currently expects to record approximately $0.8 million right-of-use assets and $1.0 million lease liabilities for all its active leases as of the adoption date in the consolidated balance sheets, and no material impact on its consolidated results of operations or cash flows. Recently Issued Accounting Pronouncements — Not Yet Adopted In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820 ) (ASU No. 2018-13), which removes, modifies and adds certain disclosure requirements on fair value measurements in Topic 820. ASU No. 2018-13 will be effective for the Company beginning January 1, 2020. Early adoption is permitted. The Company is in the process of evaluating the impact of this standard on disclosures in its consolidated financial statements.
Merger Transactions	As described in Note 1- Description of Business and Basis of Presentation, Private Evofem merged with the Company effective on the Closing Date. The Merger was accounted for as a reverse recapitalization with Private Evofem treated as the accounting acquirer pursuant to ASC 805- Business Combinations. Under reverse recapitalization accounting, the accounting acquirer shall measure the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in the acquiree at their acquisition-date fair values.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Reconciliation of Cash and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash, reported within the consolidated statements of cash flows (in thousands): Years Ended December 31, 2018 2017 Cash and cash equivalents $ 1,330 $ 1,211 Restricted cash 431 490 Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows $ 1,761 $ 1,701
Summary of Stock Option Expensing Policies	The following table summarizes the Company’s stock-based awards expensing policies for employees and nonemployees: Employees and Nonemployee Consultants After Adopting ASU 2018-07 Nonemployee Consultants Prior to Adopting ASU 2018-07 Service only condition Straight-line based on the grant date fair value Re-value at each reporting date through the service commitment date Performance criterion is probable of being met: Service criterion is complete Recognize the grant date fair value of the award(s) once the performance criterion is considered probable of occurrence Re-value the award(s) once the performance criterion is considered probable of occurrence and recognize expense for the then fair value of the award(s) Service criterion is not complete Expense using an accelerated multiple-option approach (1) over the remaining requisite service period Same as for employees, except the award will be marked-to-market through the performance commitment date Performance criterion is not probable of being met and: Is not tied to the successful completion of an initial public offering of the Company’s common stock (IPO) No expense recognition is required until the performance criterion is considered probable at which point expense is recognized using an accelerated multiple-option approach Same as for employees, except the award will be marked-to-market through the performance commitment date Is tied to the successful completion of an IPO by the Company Upon closing of an IPO by the Company, recognize the grant date fair value of the award(s) Same as for employees, except expense is recognized based upon the fair value of the Company’s common stock sold in the IPO ________________ (1) The accelerated multiple-option approach results in compensation expense being recognized for each separately vesting tranche of the award as though the award was in substance multiple awards and, therefore, results in accelerated expense recognition during the earlier vesting periods.
Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	Potentially dilutive securities excluded from the calculation of diluted net loss per share are summarized in the table below. For the year ended December 31, 2018, the shares in the table also included 1,013,375 shares of options granted out of the share reserve increase approved by the board of directors under the Amended and Restated 2014 Plan (as defined below) on November 28, 2018, and are subject to the Company obtaining the requisite stockholder approval (the Contingent Options) at the 2019 annual meeting. For the year ended December 31, 2017, the shares in the table have been adjusted to reflect the conversion of Series A, B, C-1, and C convertible preferred stock and Series D as fully described in Note 8- Convertible Preferred Stock , and the Reverse Stock Split. Years Ended December 31, 2018 2017 Convertible preferred stock — 1,027,079 Series D redeemable convertible preferred stock — 6,878,986 Unvested restricted common stock subject to repurchase — 122,149 Unvested restricted stock units — 2,566 Options to purchase common stock 5,767,627 160,248 Warrants to purchase common stock 4,775,886 — Total 10,543,513 8,191,028

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid and Other Current Assets	Prepaid and other current assets consist of the following (in thousands): Years Ended December 31, 2018 2017 Flex note receivable (1) $ 250 $ 250 Insurance 199 96 Clinical supplies 62 119 Rent 66 63 Other receivable from related parties 11 17 Other 129 108 Total $ 717 $ 653 _______________________ (1) In June 2016, Private Evofem’s board of directors committed to a plan to sell its Softcup line of business (Softcup) and re-direct its available cash resources to further develop Amphora. In July 2016, the Company entered into an Asset Purchase Agreement with The Flex Company (Flex), whereby Flex would acquire certain assets and assume certain liabilities associated with Softcup. Total consideration for the Softcup sale was $1.9 million , with $0.6 million received in cash at closing and the remaining $1.3 million due and payable under a note in favor of the Company (the Flex Note) through January 1, 2021 (the Maturity Date). The Flex Note bears simple interest at a rate of 5.0% per annum on the remaining principal amount outstanding. An annual principal payment of approximately $0.3 million and the annual accrued and unpaid interest are payable each January 1, beginning in 2017 through the Maturity Date. The Flex Note is secured by the Softcup assets and has been recorded at present value. The Company’s incremental borrowing rate and the stated interest rate of the Flex Note are materially consistent.
Property and Equipment, Net	Property and equipment, net, consists of the following (in thousands): Years Ended December 31, Useful Life 2018 2017 Research equipment 5 years $ 639 $ 639 Computer equipment and software 3 years 13 6 Office furniture 5 years 205 205 Leasehold improvements 5 years or less 340 340 1,197 1,190 Less: accumulated depreciation and amortization (604 ) (342 ) Total, net $ 593 $ 848
Other Noncurrent Assets	Other noncurrent assets consist of the following (in thousands): Years Ended December 31, 2018 2017 Flex note receivable, net of current portion $ 500 $ 750 Prepaid Directors & Officers insurance 439 — Total $ 939 $ 750
Accrued Expenses	Accrued expenses consist of the following (in thousands): Years Ended December 31, 2018 2017 Clinical studies $ 9,153 $ 8,789 Sublicense fees 1,117 2,000 Accrued interest on unpaid sublicense fees 174 76 Legal and other professional fees 549 727 Accrued franchise tax 188 12 Public offering costs 127 135 Board of directors’ fees and related expenses 67 247 Other 138 100 Total $ 11,513 $ 12,086

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured on a Recurring Basis	The fair values of the Company’s assets and liabilities, including the money market fund, Flex Note receivable and Series D 2X liquidation preference, measured on a recurring basis are summarized in the following tables, as applicable (in thousands): December 31, 2018 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Money market fund (1) $ 154 $ 154 $ — $ — Flex note receivable 750 — 750 — Total assets $ 904 $ 154 $ 750 $ — _______________________ (1) Included as a component of cash and cash equivalents on the accompanying consolidated balance sheet. December 31, 2017 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Flex note receivable $ 1,000 $ — $ 1,000 $ — Series D 2X liquidation preference (79,870 ) — — (79,870 ) Total assets (liabilities) $ (78,870 ) $ — $ 1,000 $ (79,870 )
Summary of Changes in Level 3 Financial Liabilities Measured at Fair Value on a Recurring Basis	The following table summarizes the changes in Level 3 financial liabilities measured at fair value on a recurring basis for the year ended December 31, 2018 and 2017 (in thousands). Series D 2X Liquidation Preference Liability Balance at December 31, 2016 $ 8,030 Issuance of Series D 2X liquidation preference 10,665 Change in fair value of Series D 2X liquidation preference 61,175 Balance at December 31, 2017 $ 79,870 Change in fair value of Series D 2X liquidation preference 130 Redemption of Series D 2X liquidation preference upon conversion of Series D (80,000 ) Balance at December 31, 2018 $ —

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Summary of Minimum Lease Payments	As of December 31, 2018 , future minimum lease commitments under the above mentioned operating leases, together with sublease income, are as follows (in thousands): Operating Leases Year ending December 31, 2019 $ 777 Year ending December 31, 2020 201 Total $ 978

Related-party Transactions (Tab

Related-party Transactions (Tables)	12 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Summary of Receivables, Payables, Payments and Expenses of Company's Transactions	The following table summarizes receivables, payables, payments and expenses related to the Company’s transactions with WCG Cares as of and for the years ended December 31, 2018 and 2017, respectively (in thousands): 2018 2017 Receivables $ 7 $ — Payables $ — $ 175 Payments $ 302 $ — Expenses $ 127 $ 175 The following table summarizes receivables, payables, payments and expenses related to the Company’s transactions with WCGI related entities as of and for the years ended December 31, 2018 and 2017, respectively (in thousands): 2018 2017 Receivables $ 3 $ 17 Payables $ 1,292 $ 2,077 Payments $ 883 $ 1,026 Expenses $ 98 $ 89

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
The Designated, Issued and Outstanding Shares of Convertible Preferred Stock, by Series	The designated, issued and outstanding shares of convertible preferred stock, by series, as of December 31, 2017 were as follows (aggregate liquidation amount and proceeds, net of issuance costs, in thousands): Shares Original Shares Common Aggregate Proceeds, Series A 12,768,492 $ 1.9579445 12,618,279 12,618,279 $ 24,706 $ 23,848 Series B 31,034,696 $ 3.2222 13,801,318 13,801,318 44,471 43,616 Series C-1 8,660,572 $ 3.97 8,558,686 8,558,686 33,978 34,382 Series C 5,037,784 $ 3.97 5,037,784 5,037,784 20,000 19,469 Series D (2)(3) 80 $ 500,000 80 85,160 39,739 Total 57,501,624 40,016,147 $ 208,315 $ 161,054 _______________________ (1) The Series D shares were convertible into shares in the next equity financing (either preferred or common) at a 50% discount to the fair value price per share of the shares to be issued in the next financing, therefore, the Series D common stock equivalents and the totals for common stock equivalents have been left blank. (2) Aggregate liquidation amount included accrued and unpaid dividends of $5.2 million as of December 31, 2017 . (3) Proceeds, net of issuance costs, included $35.0 million in cash and $5.0 million from the conversion of the Amended Cosmederm Note (see more discussions below) less issuance costs of approximately $0.3 million . This line excluded the Series D 2X liquidation preference net issuance price of $18.2 million , the loss on the issuance of Series D of $35.2 million , loss on extinguishment of related-party note payable of $6.7 million and accrued Series D dividends of $5.2 million . Private Evofem and Cosmederm entered a promissory note during 2015, which was amended in July 2016 in conjunction with the Private Evofem’s Series D financing (the Amended Cosmederm Note). Cosmederm assigned the Amended Cosmederm Note with the then outstanding principal balance of $10.0 million to WIM. As a condition to closing the Private Evofem’s Series D, WIM immediately converted $5.0 million of the Amended Cosmederm Note into 10 shares of the Private Evofem’s Series D and canceled the remaining $5.0 million .

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Summary of Common Stock Reserved for Future Issuance	Common stock reserved for future issuance is as follows in common equivalent shares as of December 31, 2018 : Common stock issuable upon the exercise of stock options outstanding 5,767,627 Common stock issuable upon the exercise of common stock warrants 4,775,886 Common stock available for future issuance under the 2014 ESPP 118,825 Common stock available for future issuance under the Amended and Restated 2014 Plan 74,094 Common stock available for future issuance under the Inducement Plan 156,000 Total common stock reserved for future issuance 10,892,432

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation expense related to stock options	The following table summarizes stock-based compensation expense related to stock options, RSAs and RSUs granted to employees and nonemployees included in the consolidated statements of operations as follows (in thousands): Years Ended December 31, 2018 2017 Research and development $ 3,193 $ 184 General and administrative 14,649 677 Total $ 17,842 $ 861
Summary of Stock Option Information	The following table summarizes share option activity for the year ended December 31, 2018: Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value (1) (in thousands) Outstanding as of December 31, 2017 160,248 $ 56.66 7.80 — Granted (2) 5,570,675 $ 6.33 Assumed from Neothetics (3) 246,810 $ 14.31 Exercised (6,173 ) $ 6.78 Forfeited (203,933 ) $ 11.71 Outstanding as of December 31, 2018 5,767,627 $ 7.00 9.01 $ 3,211 Options exercisable as of December 31, 2018 3,034,283 $ 9.58 8.59 $ 342 Options vested and expected to vest as of December 31, 2018 5,767,627 $ 7.00 9.01 $ 3,211 _______________________ (1) As of December 31, 2017, the fair value of the Company’s common shares as determined by its board of directors was $0.31 per share. (2) The number of shares granted included 1,013,375 shares of Contingent Options granted on November 28, 2018 out of the share reserve increase approved by the board of directors under the Amended and Restated 2014 Plan, and were subject to the Company obtaining the requisite stockholder approval at the 2019 annual meeting. (3) The number of shares assumed from Neothetics represents outstanding stock options as of January 17, 2018 owned by Neothetics' employees in conjunction with the Merger. The following table summarizes certain information regarding stock options for the years ended December 31, 2018 and 2017 (in thousands, except per share data): 2018 2017 Weighted average grant date fair value per share of options granted during the period $ 3.99 $ 32.34 Fair value per share of options vested during the period $ 4.58 $ 35.52 Cash received from options exercised during the period $ 42 $ — Intrinsic value of options exercised during the period $ 12 $ —
Weighted-average assumptions rate	The fair value of stock-based compensation for stock options granted to employees and nonemployees was estimated on the date of grant using the BSM option-pricing model based on the following weighted-average assumptions for options granted for the periods indicated. Years Ended December 31, 2018 2017 Expected volatility 87.0 % 90.9 % Risk-free interest rate 2.9 % 2.2 % Expected dividend yield — % — % Expected term (years) 5.5 5.9
Summary of Restricted Stock Awards and Restricted Stock Units	The following table summarizes RSAs and RSUs activity for the year ended December 31, 2018: Shares (RSAs) Weighted Average Fair Value per Share Shares (RSUs) Weighted Average Fair Value per Share Unvested as of December 31, 2017 122,149 $ 48.72 2,566 $ 48.72 Granted 1,230,399 $ 2.46 75,000 $ 2.46 Canceled (122,149 ) $ 48.72 (2,566 ) $ 48.72 Released (1,185,399 ) $ 2.72 (75,000 ) $ 2.46 Unvested as of December 31, 2018 45,000 $ 2.46 — $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Consolidated pretax loss from continuing operations	The Company’s consolidated pretax loss for the years ended December 31, 2018 and 2017 were generated by domestic and foreign operations as follows (in thousands): 2018 2017 United States $ (125,670 ) $ (105,222 ) Foreign (40 ) (80 ) Total $ (125,710 ) $ (105,302 )
Income tax provision from continuing operations	Income tax provision for the years ended December 31, 2018 and 2017 consisted of the following (in thousands): 2018 2017 United States $ — $ — State (2 ) (3 ) Foreign — — Total current tax provision (2 ) (3 ) Total deferred tax provision — — Total $ (2 ) $ (3 )
Reconciliation between the Companys effective tax rate on loss from continuing operations and the statutory tax rate	The reconciliation between the Company’s effective tax rate on loss before income tax and the statutory tax rate for the years ended December 31, 2018 and 2017 was as follows: 2018 2017 Statutory rate 21.00 % 34.00 % State income tax, net of federal benefit 0.21 % (0.34 )% Nondeductible expenses (0.56 )% (0.46 )% Equity-based expenses (1.03 )% (2.93 )% Loss on issuance of warrants (8.01 )% — % Change in fair value of Series D 2X liquidation preference (0.02 )% (19.75 )% Return to provision 0.03 % 0.19 % Tax credits 1.60 % 1.35 % Uncertain tax positions (0.57 )% (0.34 )% Foreign rate differential (0.01 )% (0.03 )% Rate adjustment 0.19 % (22.26 )% Change in valuation allowance (12.83 )% 10.57 % Effective tax rate — % — %
Company's net deferred tax assets arising from its taxable subsidiaries	The Company’s net deferred tax assets arising from its taxable subsidiaries consisted of the following components as of December 31, 2018 and 2017 (in thousands): 2018 2017 Deferred tax assets: Net loss carryforwards $ 53,933 $ 42,281 Fixed assets and intangibles 672 89 Research and development credits 5,948 3,808 Stock-based compensation 3,905 1,394 Other 747 846 Total deferred tax assets 65,205 48,418 Less: valuation allowance (65,205 ) (48,418 ) Net deferred tax assets $ — $ —
Activity related to the Company's gross unrecognized tax benefits	The following table summarized the activity related to the Company’s gross unrecognized tax benefits as of December 31, 2018 and 2017 (in thousands): 2018 2017 Balance at the beginning of the year $ 1,335 $ 970 Adjustments related to prior year tax positions 162 (5 ) Increases related to current year tax positions 564 370 Decreases due to statute of limitation expiration — — Balance at end of year $ 2,061 $ 1,335

Selected Quarterly Financial _2

Selected Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information	The following table contains quarterly financial information for 2018 and 2017 . The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period. First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share data) Year Ended December 31, 2018 Total operating expense $ 20,986 $ 23,242 $ 18,433 $ 14,981 Other (income) expense 48,070 — (2 ) — Net loss (69,056 ) (23,244 ) (18,431 ) (14,981 ) Net loss attributable to common stockholders (69,122 ) (23,244 ) (18,431 ) (14,981 ) Net loss per share attributable to common stockholders, basic and diluted (4.62 ) (1.11 ) (0.71 ) (0.58 ) Year Ended December 31, 2017 Total operating expense $ 4,913 $ 6,358 $ 9,070 $ 15,346 Other expense 353 154 64,961 4,147 Net loss (5,269 ) (6,512 ) (74,031 ) (19,493 ) Net loss attributable to common stockholders (6,157 ) (7,409 ) (75,085 ) (20,671 ) Net loss per share attributable to common stockholders, basic and diluted (3.14 ) (3.78 ) (38.31 ) (10.55 )

Description of Business and B_2

Description of Business and Basis of Presentation - Additional Information (Detail) $ in Thousands	May 24, 2018USD ($)	Jan. 17, 2018	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Entity Information [Line Items]
Reverse stock split, conversion ratio		166.7000
Proceeds from issuance of common stock, pre-funded warrants and common warrants in connection with the Offering, net of underwriting discounts and commissions			$ 37,542	$ 0
Stock issuance costs	$ 1,500		1,418	713
Cash and cash equivalents			1,330	1,211
Working capital deficit			(24,900)
Accumulated deficit			$ (433,146)	$ (307,277)
Evolution Pharma | Evofem
Entity Information [Line Items]
Partnership interest percent			99.00%
Evolution Pharma | Evofem Limited, LLC
Entity Information [Line Items]
Partnership interest percent			1.00%
Public Offering
Entity Information [Line Items]
Proceeds from issuance of common stock, pre-funded warrants and common warrants in connection with the Offering, net of underwriting discounts and commissions	$ 37,500		$ 36,000
Stock issuance costs			$ 1,500

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Millions	12 Months Ended
	Dec. 31, 2018Segmentshares	Dec. 31, 2017shares	Jan. 01, 2019USD ($)
Accounting Policies [Abstract]
Number of operating segments | Segment	1
Property, Plant and Equipment [Line Items]
Antidilutive securities excluded from calculation of EPS (in shares) | shares	10,543,513	8,191,028
Amended and Restated 2014 Plan
Property, Plant and Equipment [Line Items]
Antidilutive securities excluded from calculation of EPS (in shares) | shares	1,013,375
Minimum
Property, Plant and Equipment [Line Items]
Useful Life	3 years
Maximum
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Scenario Forecast | Accounting Standards Update 2016-02
Property, Plant and Equipment [Line Items]
Right-of-use asset | $			$ 0.8
Operating lease, liability | $			$ 1

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalent, and Restricted Cash (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 1,330	$ 1,211
Restricted cash	431	490
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$ 1,761	$ 1,701

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	10,543,513	8,191,028
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	0	1,027,079
Series D Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	0	6,878,986
Unvested Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	0	2,566
Stock options issued and outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	5,767,627	160,248
Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	4,775,886	0
Unvested Restricted Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	0	122,149

Merger and Related Transactio_2

Merger and Related Transactions - Additional Information (Details) $ / shares in Units, $ in Millions	Jan. 17, 2018USD ($)$ / sharesshares	Dec. 31, 2017$ / sharesshares	Dec. 31, 2018$ / sharesshares	Dec. 31, 2017$ / sharesshares
Business Acquisition [Line Items]
Common stock, shares outstanding (in shares)		2,082,053	25,867,248	2,082,053
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Maximum warrants for purchase (in shares)			4,775,886
Converted stock option plans, weighted average grant date fair value (in usd per share) | $ / shares			$ 3.99	$ 32.34
Common stock issued upon the exercise of common stock warrants (in shares)	11,875		2,000,000
Converted shares (in shares)		80
Reverse stock split, conversion ratio	166.7000
Private Evofem Plan Options
Business Acquisition [Line Items]
Conversion of stock option plans (in shares)	159,325
Converted stock option plans, weighted average grant date fair value (in usd per share) | $ / shares	$ 56.72
Invesco Warrants
Business Acquisition [Line Items]
Maximum warrants for purchase (in shares)	3,980,437
Common stock issued upon the exercise of common stock warrants (in shares)	3,968,473
Two Thousand Twelve Equity Incentive Plan | Unvested Restricted Common Stock
Business Acquisition [Line Items]
Number of cancelled shares (in shares)	122,149
Neothetics
Business Acquisition [Line Items]
Number of converted shares (in shares)	6,878,989
Common Stock
Business Acquisition [Line Items]
Exchange of shares	1
Number of converted shares (in shares)	1,027,079
Number of shares issued (in shares)	1,614,289
Consideration received | $	$ 20
Common Stock | Neothetics
Business Acquisition [Line Items]
Exchange of shares	0.1540
Number of converted shares (in shares)	85,987
Maximum warrants for purchase (in shares)	2,000,000
Common stock issued upon the exercise of common stock warrants (in shares)	2,000,000
Shares exchanged (in shares)	3
Series D
Business Acquisition [Line Items]
Converted shares (in shares)	80
Series D | Neothetics
Business Acquisition [Line Items]
Converted shares (in shares)	80
Shares issued in conversion, post split (in shares)	6,878,989
Neothetics
Business Acquisition [Line Items]
Cash and cash equivalents acquired | $	$ 1.9
Prepaids and other current assets acquired | $	0.5
Current and non current liabilities acquired | $	0.4
Common stock value | $	$ 1.9
Common stock, shares outstanding (in shares)	2,308,430
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001

Balance Sheet Details - Prepaid

Balance Sheet Details - Prepaid and Other Current Assets (Detail) - USD ($) $ in Thousands	1 Months Ended
	Jul. 31, 2016	Dec. 31, 2018	Dec. 31, 2017
Prepaid Expenses And Other Current Assets [Line Items]
Prepaid and other current assets		$ 717	$ 653
Consideration transferred	$ 1,900
Cash received	600
Payable due in consideration	$ 1,300
Interest rate	5.00%
Annual principal payment	$ 300
Flex note receivable
Prepaid Expenses And Other Current Assets [Line Items]
Prepaid and other current assets		250	250
Insurance
Prepaid Expenses And Other Current Assets [Line Items]
Prepaid and other current assets		199	96
Clinical supplies
Prepaid Expenses And Other Current Assets [Line Items]
Prepaid and other current assets		62	119
Rent
Prepaid Expenses And Other Current Assets [Line Items]
Prepaid and other current assets		66	63
Other receivable from related parties
Prepaid Expenses And Other Current Assets [Line Items]
Prepaid and other current assets		11	17
Other
Prepaid Expenses And Other Current Assets [Line Items]
Prepaid and other current assets		$ 129	$ 108

Balance Sheet Details - Propert

Balance Sheet Details - Property and Equipment, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,197	$ 1,190
Less: accumulated depreciation and amortization	(604)	(342)
Total, net	593	848
Research equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 639	639
Useful Life	5 years
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 13	6
Useful Life	3 years
Office furniture
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 205	205
Useful Life	5 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 340	$ 340
Maximum
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Maximum | Leasehold improvements
Property, Plant and Equipment [Line Items]
Useful Life	5 years

Balance Sheet Details - Additio

Balance Sheet Details - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 05, 2018	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation expense		$ 300	$ 200
Monthly interest rate permitted by Laws of the State of Massachusetts	1.00%
Notes payable	$ 4,000	$ 4,010	$ 0

Balance Sheet Details - Other N

Balance Sheet Details - Other Non Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Other noncurrent assets	$ 939	$ 750
Flex note receivable
Other noncurrent assets	500	750
Prepaid Directors & Officers insurance
Other noncurrent assets	$ 439	$ 0

Balance Sheet Details - Accrued

Balance Sheet Details - Accrued Expenses (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Clinical studies	$ 9,153	$ 8,789
Sublicense fees	1,117	2,000
Accrued interest on unpaid sublicense fees	174	76
Legal and other professional fees	549	727
Accrued franchise tax	188	12
Public offering costs	127	135
Board of directors’ fees and related expenses	67	247
Other	138	100
Total	$ 11,513	$ 12,086

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Fair Value of Company's Level 3 Financial Liabilities Measured on a Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	$ 904
Total liabilities		$ (78,870)
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	154
Total liabilities		0
Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	750	1,000
Significant Unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0
Total liabilities		(79,870)
Money market fund
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	154
Money market fund | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	154
Money market fund | Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0
Money market fund | Significant Unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0
Series D 2X liquidation preference
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total liabilities		(79,870)
Series D 2X liquidation preference | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total liabilities		0
Series D 2X liquidation preference | Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total liabilities		0
Series D 2X liquidation preference | Significant Unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total liabilities		(79,870)
Flex note receivable
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	750	1,000
Flex note receivable | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Flex note receivable | Significant Other Observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	750	1,000
Flex note receivable | Significant Unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	$ 0	$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Changes in Level 3 Financial Liabilities Measured at Fair Value on a Recurring Basis (Detail) - Significant Unobservable Inputs (Level 3) - Series D 2X liquidation preference - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Nov. 30, 2017	Aug. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Rollforward of Series D 2X Liquidation Preference Liability
Beginning balance			$ 79,870	$ 8,030
Issuance of Series D 2X liquidation preference	$ 7,900	$ 2,800		10,665
Change in fair value of Series D 2X liquidation preference			130	61,175
Redemption of Series D 2X liquidation preference upon conversion of Series D			(80,000)
Ending balance			$ 0	$ 79,870

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands	Jan. 17, 2018	Dec. 31, 2017	Nov. 30, 2017	Aug. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of converted shares (in shares)		80
Series D 2X liquidation preference
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value of financial liability					$ 80,000
Change in fair value of Series D 2X liquidation preference					$ 100	$ 61,200
Series D 2X liquidation preference | Significant Unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of Series D 2X liquidation preference			$ 7,900	$ 2,800		$ 10,665
Series D
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Convertible preferred stock, shares issued (in shares)			5	15
Number of converted shares (in shares)	80
Series D | Neothetics
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of converted shares (in shares)	80

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands

Oct. 01, 2019USD ($)

Feb. 01, 2015USD ($)

Jan. 30, 2015renewal_term

Jun. 30, 2018USD ($)

Mar. 31, 2017USD ($)

Feb. 28, 2017USD ($)

Aug. 31, 2016USD ($)

Mar. 31, 2020USD ($)

Dec. 31, 2018USD ($)claim

Dec. 31, 2017USD ($)claim

Nov. 30, 2019USD ($)

Apr. 01, 2018

Loss Contingencies [Line Items]

Operating lease termination fee payment

$ 55

Number of renewal periods | renewal_term

2

Renewal period

5 years

Restricted cash

$ 431

$ 490

Rent expense

$ 600

$ 500

Claims | claim

0

0

Accrued sublicense fees

$ 1,117

$ 2,000

Accrued interest on unpaid sublicense fees

174

76

LJ Gateway Office LLC

Loss Contingencies [Line Items]

Discount percent

50.00%

Base rent

$ 28

Surrendered lease security deposit

$ 30

Percent of base rate increase

3.00%

Repayment of the sublessee

$ 30

Woman Care Global International

Loss Contingencies [Line Items]

Percentage of sublease

25.00%

Security deposit by sublease

200

Sublease arrangement, percent of overall lease payment

20.00%

Sublease income as a reduction of rent expense

100

200

Woman Care Global International | Sublicense Agreement

Loss Contingencies [Line Items]

Upfront license payment

$ 10,000

Maximum milestone license payment

$ 32,000

Accrued sublicense fees

1,100

2,000

Accrued interest on unpaid sublicense fees

200

100

Woman Care Global International | Initial Payment

Loss Contingencies [Line Items]

Security deposit by sublease

$ 300

Securities Deposit

Loss Contingencies [Line Items]

Restricted cash

$ 300

$ 400

Scenario Forecast

Loss Contingencies [Line Items]

Periodic release of security deposit

$ 66

$ 5

Scenario Forecast | Woman Care Global International | Sublicense Agreement

Loss Contingencies [Line Items]

Annual sublicense fees

$ 5,000

Commitments and Contingencies_2

Commitments and Contingencies - Summarized Future Minimum Lease Commitments (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
Year ending December 31, 2019	$ 777
Year ending December 31, 2020	201
Total	$ 978

Related-party Transactions - Ad

Related-party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands

Jul. 31, 2018

Jul. 02, 2018

Mar. 12, 2018

Apr. 01, 2017

Apr. 01, 2016

Mar. 31, 2018

Oct. 31, 2017

Feb. 28, 2013

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2015

Jan. 17, 2018

Related Party Transaction [Line Items]

Stock option warrant to purchase common stock (in shares)

2,000,000

11,875

Stock option warrant to purchase, exercise price per share

$ 6.23

General and administrative

$ 34,227

$ 12,148

President and CEO

Related Party Transaction [Line Items]

Compensation relates management service

$ 50

Accrued compensation (excluding board fees)

100

100

Woman Care Global International

Related Party Transaction [Line Items]

General and administrative

300

Revenue from related parties

100

800

Corporate sponsorship payment

$ 300

Related party transaction cost

0

200

Woman Care Global International | License and Service

Related Party Transaction [Line Items]

Annual sublicense fees

$ 5,000

WCG Cares

Related Party Transaction [Line Items]

Corporate sponsorship payment

$ 100

Women Deliver

Related Party Transaction [Line Items]

Related party transaction cost

$ 200

Unvested Restricted Stock Units (RSUs)

Related Party Transaction [Line Items]

Issued RSU for the right to shares common stock

75,000

Unvested Restricted Stock Units (RSUs) | Chairman | Amended And Restated 2014 Plan

Related Party Transaction [Line Items]

Issued RSU for the right to shares common stock

75,000

2016 Consulting Agreement | Thomas Lynch

Related Party Transaction [Line Items]

Compensation relates management service

$ 400

Compensation paid

$ 300

300

2016 Consulting Agreement | Thomas Lynch | Board service

Related Party Transaction [Line Items]

Compensation relates management service

$ 100

2016 Consulting Agreement | Warrants | Thomas Lynch

Related Party Transaction [Line Items]

Vesting period

1 year

2016 Consulting Agreement | Common Stock | Thomas Lynch

Related Party Transaction [Line Items]

Vesting period

1 year

Stock option warrant to purchase common stock (in shares)

3,850

Stock option warrant to purchase, exercise price per share

$ 46.36

2016 Consulting Agreement | Unvested Restricted Stock Units (RSUs) | Thomas Lynch

Related Party Transaction [Line Items]

Stock option warrant to purchase common stock (in shares)

2,566

2017 Consulting Agreement | Thomas Lynch

Related Party Transaction [Line Items]

Vesting period

36 months

2 years

Stock option warrant to purchase common stock (in shares)

85,500

225,000

6,416

Stock option warrant to purchase, exercise price per share

$ 2.10

$ 7.29

Stock option share vested

125,000

Compensation relates management service

$ 400

Compensation paid

$ 300

$ 300

2017 Consulting Agreement | Thomas Lynch | Board service

Related Party Transaction [Line Items]

Compensation relates management service

$ 100

Grant Agreement | Woman Care Global International

Related Party Transaction [Line Items]

Grant agreement term

3 years

Amount of funding provided

$ 4,000

Related-party Transactions - Su

Related-party Transactions - Summary of Receivables, Payables, Payments and Expenses of Company's Transactions (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Woman Care Global International
Related Party Transaction [Line Items]
Receivables	$ 3	$ 17
Payables	1,292	2,077
Payments	883	1,026
Expenses	98	89
WCG Cares
Related Party Transaction [Line Items]
Receivables	7	0
Payables	0	175
Payments	302	0
Expenses	$ 127	$ 175

Convertible Preferred Stock - C

Convertible Preferred Stock - Convertible Preferred Stock Issued and Outstanding (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Nov. 30, 2017	Aug. 31, 2017
Series D
Temporary Equity [Line Items]
Shares Issued (in shares)			5	15
Preferred Stock
Temporary Equity [Line Items]
Shares Designated (in shares)	57,501,624	5,000,000
Original Issue Price (in dollars per share)	$ 0.0001	$ 0.0001
Shares Issued (in shares)	40,016,147
Shares Outstanding (in shares)	40,016,147
Aggregate Liquidation Amount	$ 208,315
Proceeds, Net of Issuance Costs	$ 161,054
Preferred Stock | Series A
Temporary Equity [Line Items]
Shares Designated (in shares)	12,768,492
Original Issue Price (in dollars per share)	$ 1.9579445
Shares Issued (in shares)	12,618,279
Shares Outstanding (in shares)	12,618,279
Common Stock Equivalents (in shares)	12,618,279
Aggregate Liquidation Amount	$ 24,706
Proceeds, Net of Issuance Costs	$ 23,848
Preferred Stock | Series B
Temporary Equity [Line Items]
Shares Designated (in shares)	31,034,696
Original Issue Price (in dollars per share)	$ 3.2222
Shares Issued (in shares)	13,801,318
Shares Outstanding (in shares)	13,801,318
Common Stock Equivalents (in shares)	13,801,318
Aggregate Liquidation Amount	$ 44,471
Proceeds, Net of Issuance Costs	$ 43,616
Preferred Stock | Series C-1
Temporary Equity [Line Items]
Shares Designated (in shares)	8,660,572
Original Issue Price (in dollars per share)	$ 3.97
Shares Issued (in shares)	8,558,686
Shares Outstanding (in shares)	8,558,686
Common Stock Equivalents (in shares)	8,558,686
Aggregate Liquidation Amount	$ 33,978
Proceeds, Net of Issuance Costs	$ 34,382
Preferred Stock | Series C
Temporary Equity [Line Items]
Shares Designated (in shares)	5,037,784
Original Issue Price (in dollars per share)	$ 3.97
Shares Issued (in shares)	5,037,784
Shares Outstanding (in shares)	5,037,784
Common Stock Equivalents (in shares)	5,037,784
Aggregate Liquidation Amount	$ 20,000
Proceeds, Net of Issuance Costs	$ 19,469
Preferred Stock | Series D
Temporary Equity [Line Items]
Shares Designated (in shares)	80
Original Issue Price (in dollars per share)	$ 500,000
Shares Issued (in shares)	80
Shares Outstanding (in shares)	80
Aggregate Liquidation Amount	$ 85,160
Proceeds, Net of Issuance Costs	$ 39,739

Convertible Preferred Stock - A

Convertible Preferred Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	May 24, 2018	Jan. 17, 2018	Dec. 31, 2017	Jul. 31, 2017	Jul. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Jan. 18, 2018
Temporary Equity [Line Items]
Number of converted shares (in shares)			80
Cash dividends						$ 200
Accrued and unpaid dividends			$ 5,200				$ 5,200
Issuance costs	$ 1,500					1,418	713
Loss on issuance of redeemable convertible preferred stock						$ 0	$ 8,522
Number of shares of to purchase capital stock (in shares)		11,875				2,000,000
Stock option warrant to purchase, exercise price per share						$ 6.23
Warrants fair value								$ 14,100
Neothetics
Temporary Equity [Line Items]
Number of converted shares (in shares)		6,878,989
Cosmederm | Amended Cosmederm Note
Temporary Equity [Line Items]
Number of converted shares (in shares)					10
Outstanding debt					$ 10,000
Converted debt					5,000
Canceled convertible debt					$ 5,000
Common Stock
Temporary Equity [Line Items]
Number of converted shares (in shares)		1,027,079
Consideration received		$ 20,000
Common Stock | Neothetics
Temporary Equity [Line Items]
Number of converted shares (in shares)		85,987
Shares exchanged (in shares)		3
Number of shares of to purchase capital stock (in shares)		2,000,000
Stock option warrant to purchase, exercise price per share						$ 8.35
Convertible Preferred Stock
Temporary Equity [Line Items]
Shares issued (in shares)						0
Shares outstanding (in shares)						0
Issuance and sale of an aggregate shares (in shares)		5,000,000
Series D
Temporary Equity [Line Items]
Number of converted shares (in shares)		80
Shares issuable upon conversion, percentage of discount to the issuance price							50.00%
Accrued dividend			5,200				$ 5,200
Loss on issuance of redeemable convertible preferred stock							35,200
Percent of purchase price paid						(75.00%)
Number of shares of Series D to purchase capital stock, value						$ 30,000
Series D | WIM
Temporary Equity [Line Items]
Issuance and sale of an aggregate shares (in shares)				80
Consideration received				$ 500
Series D | Cosmederm Biosciences Inc
Temporary Equity [Line Items]
Issuance costs							300
Series D | Cash
Temporary Equity [Line Items]
Proceeds, net of issuance costs							35,000
Series D | Conversion Of Notes | Cosmederm Biosciences Inc
Temporary Equity [Line Items]
Proceeds, net of issuance costs							5,000
Series D | Notes Payable To Related Party | Cosmederm Biosciences Inc
Temporary Equity [Line Items]
Loss on extinguishment of related-party note payable							6,700
Series D | Neothetics
Temporary Equity [Line Items]
Number of converted shares (in shares)		80
Series D Two Convertible Preferred Stock
Temporary Equity [Line Items]
Liquidation preference			$ 18,200				$ 18,200
Series D excluding Series D 2X Liquidation Preference
Temporary Equity [Line Items]
Warrant maturity						7 years

Public Offering - Additional In

Public Offering - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 26, 2018	May 24, 2018	Dec. 31, 2018	Dec. 31, 2017	Jan. 17, 2018
Subsidiary, Sale of Stock [Line Items]
Common stock issued upon the exercise of common stock warrants (in shares)			2,000,000		11,875
Stock option warrant to purchase, exercise price per share			$ 6.23
Warrants issued in connection with Public Offering (in shares)		8,500,000
Proceeds from issuance of common stock, pre-funded warrants and common warrants in connection with the Offering, net of underwriting discounts and commissions			$ 37,542	$ 0
Issuance costs		$ 1,500	1,418	$ 713
Pre-funded warrants
Subsidiary, Sale of Stock [Line Items]
Common stock issued upon the exercise of common stock warrants (in shares)		1,063,829
Offering price of warrants (in usd per share)		$ 4.68
Stock option warrant to purchase, exercise price per share		$ 0.01
Common warrants
Subsidiary, Sale of Stock [Line Items]
Common stock issued upon the exercise of common stock warrants (in shares)		1,700,000
Offering price of warrants (in usd per share)		$ 0.01
Stock option warrant to purchase, exercise price per share		7.50
Public Offering
Subsidiary, Sale of Stock [Line Items]
Price per share (in usd per share)		$ 4.69
Proceeds from issuance of common stock, pre-funded warrants and common warrants in connection with the Offering, net of underwriting discounts and commissions		$ 37,500	36,000
Issuance costs			$ 1,500
Public Offering | Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of shares issued (in shares)		7,436,171
Over-allotment option | Common warrants
Subsidiary, Sale of Stock [Line Items]
Number of shares issued (in shares)	912
Common stock issued upon the exercise of common stock warrants (in shares)	182

Stockholders' Deficit - Additio

Stockholders' Deficit - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Feb. 05, 2019	Jun. 26, 2018	May 24, 2018	Jan. 17, 2018	Dec. 31, 2018	Jan. 18, 2018	Dec. 31, 2017	Dec. 01, 2015
Class Of Stock [Line Items]
Warrants outstanding (in shares)					4,775,886
Stock option warrant to purchase, exercise price per share					$ 6.23
Common stock issued upon the exercise of common stock warrants (in shares)				11,875	2,000,000
Common stock, shares authorized				300,000,000	300,000,000		4,051,137
Common stock, par value (in dollars per share)				$ 0.0001	$ 0.0001		$ 0.0001
Common stock, shares issued					25,867,248		2,082,053
Warrants fair value						$ 14.1
Common Stock
Class Of Stock [Line Items]
Common stock issued on vesting of restricted stock awards (in shares)					1,305,399
Invesco Asset Management
Class Of Stock [Line Items]
Warrants fair value				$ 47.9
Invesco Asset Management | Common Stock
Class Of Stock [Line Items]
Shares issued upon exercise (in shares)					3,968,473
Convertible Preferred Stock
Class Of Stock [Line Items]
Issuance and sale of an aggregate shares (in shares)				5,000,000
Preferred stock par value (in dollars per share)				$ 0.0001
Common Stock
Class Of Stock [Line Items]
Number of shares issued (in shares)				1,614,289
Common Stock | Invesco Asset Management
Class Of Stock [Line Items]
Common stock issued upon the exercise of common stock warrants (in shares)				3,980,437
Common stock, shares issued				3,968,473
Public Offering | Common Stock
Class Of Stock [Line Items]
Number of shares issued (in shares)			7,436,171
Controlled Equity Offering Sales Agreement
Class Of Stock [Line Items]
Common stock, par value (in dollars per share)								$ 0.0001
Offering price of shares								$ 20
Pre-funded warrants
Class Of Stock [Line Items]
Stock option warrant to purchase, exercise price per share			$ 0.01
Common stock issued upon the exercise of common stock warrants (in shares)			1,063,829
Common warrants
Class Of Stock [Line Items]
Stock option warrant to purchase, exercise price per share			$ 7.50
Common stock issued upon the exercise of common stock warrants (in shares)			1,700,000
Term of warrants					7 years
Common warrants | Over-allotment option
Class Of Stock [Line Items]
Common stock issued upon the exercise of common stock warrants (in shares)		182
Term of warrants					7 years
Number of shares issued (in shares)		912
Subsequent Event
Class Of Stock [Line Items]
Stock option warrant to purchase, exercise price per share	$ 2.64
Proceeds from warrant exercises	$ 6.3
Subsequent Event | Warrants
Class Of Stock [Line Items]
Shares issued upon exercise (in shares)	2,376,062
Subsequent Event | Reload Warrants
Class Of Stock [Line Items]
Stock option warrant to purchase, exercise price per share	$ 5.20
Common stock issued upon the exercise of common stock warrants (in shares)	1,188,029
RSAs and RSUs
Class Of Stock [Line Items]
Common stock issued on vesting of restricted stock awards (in shares)					622,737

Stockholders' Deficit - Summary

Stockholders' Deficit - Summary of Common Stock Reserved for Future Issuance (Detail)	Dec. 31, 2018shares
Class Of Stock [Line Items]
Common stock issuable upon the exercise of common stock warrants (in shares)	4,775,886
Total common stock reserved for future issuance (in shares)	10,892,432
Stock options issued and outstanding
Class Of Stock [Line Items]
Common stock issuable upon the exercise of stock options outstanding (in shares)	5,767,627
2014 ESPP | Stock options issued and outstanding
Class Of Stock [Line Items]
Common stock available for future issuance under 2014 ESPP (in shares)	118,825
Amended And Restated 2014 Plan | Stock options issued and outstanding
Class Of Stock [Line Items]
Common stock available for future issuance under the Amended and Restated 2014 Plan and Inducement Plan (in shares) (in shares)	74,094
Inducement Plan
Class Of Stock [Line Items]
Common stock available for future issuance under the Amended and Restated 2014 Plan and Inducement Plan (in shares) (in shares)	156,000

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Detail) - USD ($)	Jul. 02, 2018	Jan. 17, 2018	Sep. 30, 2016	Nov. 30, 2014	Sep. 30, 2012	Dec. 31, 2018	Dec. 31, 2017	Nov. 28, 2018	Jul. 24, 2018	Mar. 09, 2018	Sep. 15, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)				28,333
Total						$ 17,842,000	$ 861,000
Unrecognized stock-based compensation expense for employee stock options						$ 5,100,000
Weighted-average remaining period						2 years 2 months 26 days
Percent of eligible compensation				15.00%
Percent of issued and outstanding shares				1.00%
Shares of common stock purchased under the ESPP (in shares)						0	0
Stock options issued and outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)						5,570,675
Total						$ 14,700,000	$ 900,000
Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued RSU for the right to shares common stock						1,230,399
Unvested Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued RSU for the right to shares common stock						75,000
RSAs and RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total						$ 3,200,000	$ 0
Compensation costs not yet recognized						$ 100,000
Period for recognition						8 months 12 days
Two Thousand Twelve Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period					10 years
Two Thousand Twelve Equity Incentive Plan | Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested shares canceled (in shares)		122,149
Issued RSU for the right to shares common stock			122,149
Two Thousand Twelve Equity Incentive Plan | Unvested Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense for employee stock options						$ 0
Unvested shares canceled (in shares)		2,566
Amended And Restated 2014 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)								7,800,000		5,300,000	749,305
Incremental number of shares authorized (in shares)								2,500,000
Amended And Restated 2014 Plan | Contingent Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares remain available for future grant (in shares)						1,013,375
Amended And Restated 2014 Plan | Stock options issued and outstanding
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares remain available for future grant (in shares)						74,094
Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares remain available for future grant (in shares)						156,000
Number of shares authorized (in shares)									250,000
Vesting period one | Two Thousand Twelve Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					4 years
Percent exercisable					25.00%
Vesting period two | Two Thousand Twelve Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period					3 years
Percent exercisable					25.00%
Chairman | Two Thousand Twelve Equity Incentive Plan | Unvested Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued RSU for the right to shares common stock						2,566
Chairman | Amended And Restated 2014 Plan | Unvested Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued RSU for the right to shares common stock	75,000
Executive management team | Amended And Restated 2014 Plan | Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued RSU for the right to shares common stock	1,230,399
Executive management team | Vesting period one | Amended And Restated 2014 Plan | Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued RSU for the right to shares common stock	10,000
Executive management team | Vesting period two | Amended And Restated 2014 Plan | Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued RSU for the right to shares common stock	35,000
Executive management team | Vesting period three | Amended And Restated 2014 Plan | Unvested Restricted Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued RSU for the right to shares common stock	1,150,399

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Stock-based Compensation Expense Related to Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 17,842	$ 861
Other receivable from related parties
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	3,193	184
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total	$ 14,649	$ 677

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Fair value of common stock (in usd per share)		$ 0.31
Stock options issued and outstanding
Options
Beginning outstanding (in shares)	160,248
Granted (in shares)	5,570,675
Assumed from Neothetics (in shares)	246,810
Exercised (in shares)	(6,173)
Forfeited (in shares)	(203,933)
Ending outstanding (in shares)	5,767,627	160,248
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Beginning outstanding (in usd per share)	$ 56.66
Granted (in usd per share)	6.33
Assumed from Neothetics (in usd per share)	14.31
Exercised (in usd per share)	6.78
Forfeited (in usd per share)	11.71
Ending outstanding (in usd per share)	$ 7	$ 56.66
Weighted Average Remaining Contractual Term (in Years)	9 years 4 days	7 years 9 months 18 days
Aggregate Intrinsic Value	$ 3,211,000	$ 0
Exercisable (in shares)	3,034,283
Exercisable (in usd per share)	$ 9.58
Exercisable, Weighted Average Remaining Contractual Term (in Years)	8 years 7 months 2 days
Exercisable, Aggregate Intrinsic Value	$ 342,000
Options Vested and Expected to Vest (in shares)	5,767,627
Options Vested and Expected to Vest, Weighted Average Exercise Price (in usd per share)	$ 7
Options Vested and Expected to Vest, Weighted Average Remaining Contractual Term	9 years 4 days
Options Vested and Expected to Vest, Aggregate Intrinsic Value	$ 3,211,000
Contingent Options | Stock options issued and outstanding
Options
Granted (in shares)	1,013,375

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Estimated Fair Value of Option Award Granted Determined Using Black-Scholes Option-Pricing Valuation Model (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected volatility	87.00%	90.90%
Risk-free interest rate	2.90%	2.20%
Expected dividend yield	0.00%	0.00%
Expected term (years)	5 years 6 months	5 years 10 months 25 days

Stock-based Compensation - Rest

Stock-based Compensation - Restricted Stock Units and Awards Activity (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested beginning (in shares) | shares	122,149
Granted (in shares) | shares	1,230,399
Canceled (in shares) | shares	(122,149)
Released (in shares) | shares	(1,185,399)
Unvested ending (in shares) | shares	45,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning unvested Weighted Average Fair Value per Share (in usd per share) | $ / shares	$ 48.72
Granted (in usd per share) | $ / shares	2.46
Canceled (in usd per share) | $ / shares	48.72
Released (in usd per share) | $ / shares	2.72
Ending unvested Weighted Average Fair Value per Share (in usd per share) | $ / shares	$ 2.46
RSUs
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested beginning (in shares) | shares	2,566
Granted (in shares) | shares	75,000
Canceled (in shares) | shares	(2,566)
Released (in shares) | shares	(75,000)
Unvested ending (in shares) | shares	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning unvested Weighted Average Fair Value per Share (in usd per share) | $ / shares	$ 48.72
Granted (in usd per share) | $ / shares	2.46
Canceled (in usd per share) | $ / shares	48.72
Released (in usd per share) | $ / shares	2.46
Ending unvested Weighted Average Fair Value per Share (in usd per share) | $ / shares	$ 0

Stock-based Compensation - St_2

Stock-based Compensation - Stock Option Grant Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant date fair value per share of options granted during the period (in usd per share)	$ 3.99	$ 32.34
Fair value per share of options vested during period (in usd per share)	$ 4.58	$ 35,520
Cash received from options exercised during the period	$ 42	$ 0
Intrinsic value of options exercised during the period	$ 12	$ 0

Employee Benefits - Additional

Employee Benefits - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Postemployment Benefits [Abstract]
Company contribution percentage	3.00%
Company contributions amount	$ 0.1	$ 0.1

Income Taxes - Consolidated Pre

Income Taxes - Consolidated Pretax Loss from Continuing Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
United States	$ (125,670)	$ (105,222)
Foreign	(40)	(80)
Total	$ (125,710)	$ (105,302)

Income Taxes - Income Tax Provi

Income Taxes - Income Tax Provision from Continuing Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
United States	$ 0	$ 0
State	(2)	(3)
Foreign	0	0
Total current tax provision	(2)	(3)
Total deferred tax provision	0	0
Total	$ (2)	$ (3)

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation between Effective Tax Rate and Statutory Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Statutory rate	21.00%	34.00%
State income tax, net of federal benefit	0.21%	(0.34%)
Nondeductible expenses	(0.56%)	(0.46%)
Equity-based expenses	(1.03%)	(2.93%)
Loss on issuance of warrants	(8.01%)	(0.00%)
Change in fair value of Series D 2X liquidation preference	(0.02%)	(19.75%)
Return to provision	0.03%	0.19%
Tax credits	1.60%	1.35%
Uncertain tax positions	(0.57%)	(0.34%)
Foreign rate differential	(0.01%)	(0.03%)
Rate adjustment	0.19%	(22.26%)
Change in valuation allowance	(12.83%)	10.57%
Effective tax rate	0.00%	0.00%

Income Taxes - Summary of Compo

Income Taxes - Summary of Components of Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net loss carryforwards	$ 53,933	$ 42,281
Fixed assets and intangibles	672	89
Research and development credits	5,948	3,808
Stock-based compensation	3,905	1,394
Other	747	846
Total deferred tax assets	65,205	48,418
Less: valuation allowance	(65,205)	(48,418)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Examination [Line Items]
Valuation allowances	$ 65,205	$ 48,418
Federal statutory tax rate	21.00%	34.00%
Decrease related to its deferred tax asset	$ 200	$ 18,400
Federal
Income Tax Examination [Line Items]
Net operating loss (NOL) carryforwards	227,900
Tax credit carryforwards	6,800	4,100
State
Income Tax Examination [Line Items]
Net operating loss (NOL) carryforwards	106,700
Tax credit carryforwards	1,500	$ 1,200
Foreign
Income Tax Examination [Line Items]
Net operating loss (NOL) carryforwards	$ 600

Income Taxes - Gross Unrecogniz

Income Taxes - Gross Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at the beginning of the year	$ 1,335	$ 970
Adjustments related to prior year tax positions	162
Adjustments related to prior year tax positions		(5)
Increases related to current year tax positions	564	370
Decreases due to statute of limitation expiration	0	0
Balance at end of year	$ 2,061	$ 1,335

Selected Quarterly Financial _3

Selected Quarterly Financial Data (unaudited) - Operating Results by Quarter (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Total operating expense	$ 14,981	$ 18,433	$ 23,242	$ 20,986	$ 15,346	$ 9,070	$ 6,358	$ 4,913	$ 77,642	$ 35,687
Other (income) expense	0	(2)	0	48,070	4,147	64,961	154	353	(48,068)	(69,615)
Net loss	(14,981)	(18,431)	(23,244)	(69,056)	(19,493)	(74,031)	(6,512)	(5,269)	(125,712)	(105,305)
Net loss attributable to common stockholders	$ (14,981)	$ (18,431)	$ (23,244)	$ (69,122)	$ (20,671)	$ (75,085)	$ (7,409)	$ (6,157)	$ (125,778)	$ (109,322)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (0.58)	$ (0.71)	$ (1.11)	$ (4.62)	$ (10.55)	$ (38.31)	$ (3.78)	$ (3.14)	$ (5.74)	$ (55.78)

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	Feb. 05, 2019	Feb. 25, 2019	Dec. 31, 2018	Jan. 17, 2018	Nov. 30, 2014
Subsequent Event [Line Items]
Stock option warrant to purchase, exercise price per share (in usd per share)			$ 6.23
Common stock issued upon the exercise of common stock warrants (in shares)			2,000,000	11,875
Number of shares approved (in shares)					28,333
Subsequent Event
Subsequent Event [Line Items]
Percent of purchase price paid	80.00%
Stock option warrant to purchase, exercise price per share (in usd per share)	$ 2.64
Proceeds from warrant exercises	$ 6.3
Warrants | Subsequent Event
Subsequent Event [Line Items]
Shares issued upon exercise (in shares)	2,376,062
Reload Warrants | Subsequent Event
Subsequent Event [Line Items]
Percent of purchase price paid	160.00%
Stock option warrant to purchase, exercise price per share (in usd per share)	$ 5.20
Common stock issued upon the exercise of common stock warrants (in shares)	1,188,029
Performance-based RSAs | Subsequent Event
Subsequent Event [Line Items]
Number of shares approved (in shares)		460,500